AP507A - Novel insecticidal 2,4-diaminoquinazolines. - Google Patents
Novel insecticidal 2,4-diaminoquinazolines. Download PDFInfo
- Publication number
- AP507A AP507A APAP/P/1996/000796A AP9600796A AP507A AP 507 A AP507 A AP 507A AP 9600796 A AP9600796 A AP 9600796A AP 507 A AP507 A AP 507A
- Authority
- AP
- ARIPO
- Prior art keywords
- grams
- mole
- compound
- phenyl
- diamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dentistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Novel quinazolines having the structure
Description
NOVEL INSECTICIDAL 2.4-DIAMINQQUINAZOLINES
This invention relates to novel quinazoline compounds which are useful for controlling insects in agricultural crops. Still more particularly, this invention relates to certain 2,4-diaminoquinazoline compounds which may be used as insecticides against a variety of insects, including larvae, such as the tobacco budworm.
In accordance with the present invention it has been found that these substituted 2,4-diaminoquinazolines, and agriculturally acceptable salts thereof, when present in insecticidally effective amounts, and with a suitable agricultural carrier, are useful as active ingredients in insecticidal compositions and methods for using the same. These novel compounds, as illustrated by Compounds 43-45, 47-74,106-138,142-173, and 176-182 of Table 1 below, include the following quinazolines, which may be prepared by methods that are provided in detail in the preparative Examples 1-3, 5, and 16-19:
AP/P/ 9 4/ 0 0 7 9 6 wherein
R' is hydrogen or lower alkyl;
R2 is hydrogen, lower alkyl, lower alkylcarbonyl [e.g., -C(=O)CH, or -C(=O)C(CH,)J, 25 or lower alkoxycarbonyl [e.g., -C(=O)OC(CHJJ; or R1 and R2, taken together, form the group -R’-O-R5, wherein R5 is lower alkylene;
R* is hydrogen;
R7 is hydrogen, lower alkylcarbonlyl [e.g., -C(=O)CH,, or -C(=O)C(CH,)J, or lower alkoxycarbonyl [e.g., -C(=O)OC(CH,)];
W is selected from hydrogen, halogen, lower alkyl, lower haioalkyl, phenyl, and phenyl substituted with lower alkyl or lower haioalkyl, with the proviso that when X is phenyl, W is other than hydrogen;
Y and Z are selected from hydrogen, halogen, and phenyl; and X is selected from (a) phenyl;
BAD ORIGINAL (b) substituted aryl, [e.g., phenyl] i.e., aryl substituted with one or more of halogens (e.g., Cl, F), lower alkyl (e.g., -CH3), lower haloalkyl (e.g., -CF3), lower alkoxy (e.g., -OCH3), lower alkylthio (e.g., -SC4H9), lower alkylsulfonyl (e.g., -SO2C2H5, or -SO2C4H9), formyl, lower alkoxycarbonyl [e.g., -C(=O)OCH3], phenyl or phenyl substituted with one or more halogens (e.g., Cl, F) or lower haloalkyl (e.g., -CF3), phenoxy, or phenoxy substituted with one or more halogens (e.g., Cl, F), lower haloalkoxy, lower alkoxyalkyl, carboxy, cyano, nitro, aminocarbonyl, lower alkylcarbonylamino, lower alkylsulfonylamino;
or substituted phenyl of the formula
(X) wherein R3 is hydrogen; alkyl, (e.g. methyl, n-pentyl, or undecyl); tri(lower alkyl)silylalkyl; (4-halophenyl)lower alkyl; pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-alkylsulfonylphenoxy)alkyl;
(c) naphthyl;
(d) thienyl or thienyl substituted with halogen, lower alkyl, or haloalkyl;
(e) aroyl or substituted aroyi of the formula;
wherein V, W*. X’, Y’, and Z* are independently selected from hydrogen, halogen, haloalkyl, cyano, carboxy, lower aikoxycarbonyl, and phenyl substituted with halogen or haloalkyl;
(XI) (f) (aryl)(halo)alkenyl of the formula;
AP. Ο Ο 5 Ο 7
(ΧΠ) wherein V, W”, X, Y, and Z are independently selected from hydrogen, halogen, lower alkyl, lower haloalkyi, cyano, carboxy, lower alkoxycarbonyl, and aminocarbonyl;
and (g) 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2-dimethyl-3-benzofuranon-4-yl.
Preferred amongst the above novel quinazolines are those of Formula IX wherein R1, R2, R6. R7. Y and Z are hydrogen; W is methyl; and X is (i) phenyl substituted with one or more of fluoro, chloro, or trifluoromethyl; (ii)
AP/P/ 9 4 / 0 0 7 9 6
where V, W”, X”, Y”, and Z” are independently selected from hydrogen, trifluoromethyl, or 2,3-dihydro-2-2,dimethylbenzofuran-4-yl; 2,3-dihydro2,2-dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran4-yl; 5-halO’2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2dimethyl-3-benzofuranon-4-yl.
BAD ORIGINAL A
Each of the above novel substituted phenyl quinazoline compounds 0£I S£ falling within the scope of Formula (I) are preferred because of their high insecticidal activity, and may be used in controlling insects by applying to the locus where control is desired an insecticidal amount of these compounds admixed in a suitable agricultural carrier. When thus applied to insect-infected crops such as cotton, vegetables, fruits or other crops, these compounds are highly effective against an array of insects, particularly those shown in the tables below.
0 For the purposes of this invention, as regards the above substituent groups, the following definitions apply:
The term alkyl, alone or as part of a larger moiety, includes straight or branched chained alkyl groups of 1 to 14 carbon atoms, preferably lower straight or branched alkyl of 1 to 6 carbon atoms; while halogen includes
5 chlorine, bromine, fluorine and iodine atoms. The terms haloalkyl and haloalkoxy include straight or branched chain alkyl of 1 to 14 carbon atoms, preferably lower straight or branched alkyl of 1 to 6 carbon atoms, wherein one or more hydrogen atoms have been replaced with halogen atoms, as, for example, trifluoromethyl and 2,2,2-trifluoroethoxy,
0 respectively. The terms lower alkoxy and lower dialkylamino include those moieties having 1 to 6 carbon atoms, e.g., ethoxy and N.N-dimethylamino, respectively.
The terms aryl and substituted aryl include phenyl and naphthyl, preferably phenyl or substituted phenyl, while the terms aroyl and
5 substituted aroyl include benzoyl and naphthoyl, preferably benzoyl or substituted benzoyl.
The term ’substituted as described above, when applied to the substituted aryl, aroyl, and thienyl moieties of W, X, Y, and Z in formula I, above, includes such substituents as lower alkyl, halogen, lower haloalkyl,
0 lower alkoxy, lower haloalkoxy, lower alkoxyalkyl, carboxy, lower alkoxycarbonyl, cyano, nitro, aminocarbonyl, lower alkylsulfonyl, lower alkylcarbonylamino, lower alkylsulfonylamino. lower alkylthio, lower alkylsulfonyl, formyl, lower alkoxycarbonyl, phenyl, phenyl substituted with one or more halogens or lower haloalkyl, phenoxy, phenoxy substituted
5 with one or more halogens, arylalkoxy, arylalkoxy substituted with halogen
AP.oo 50 7 or lower alkyl, aryloxyalkoxy, aryloxyalkoxy substituted with -SO2 lower alkyl or lower alkyl, or dialkylsilylalkoxy.
Groups other than aryl, aroyl, and thienyl which may also be substituted include arylalkylamino or arylaminoalkyl (where the aryl groups may be substituted with e.g., lower alkoxy or carboxyalkoxy); arylalkylimino (where the aryl group may be substituted with, e.g., lower alkoxy); arylalkycarbonylamino (where the aryl group may be substituted with, e.g. halogen); (aryl)(alkyl)aminoalkyl (where the aryl group may be substituted with, e.g. dicarboxyalkylaminocarbonyl); and (aryl)(halo)alkenyl (where the
0 aryl group may be substituted with halogen, lower alkyl, lower haloalkyl, cyano, carboxy, lower alkoxycarbonyl, or aminocarbonyl).
Illustrations of the substituted phenyl groups further include such moieties as:
OR3
halo wherein R3 is hydrogen; alkyl,( e.g. methyl, n-pentyl, or undecyl); tri(lower alky,)sily,alkyl; (4-halophenyl)lower alkyl;
pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-aikylsulfonylphenoxy)alkyl, or the like.
In addition, the term arylalkyl includes 2-(naphth-2-yl)ethyl; arylalkenyl includes 2-(naphth-2-yl)ethenyl; arylthio includes 3,4-dichlorophenylthio
5 and naphth-2-ylthio; arylsulfinyl includes 3,4-dichlorophenylsulfinyl and naphth-2-ylsulfinyl; while ary,sulfonyl includes 3,4-dichlorophenylsulfonyl and naphth-2-ylsulfonyl.
Synthesis of The Compounds
0 The compounds employed as insecticides in accordance with this invention are generally known to those skilled in the art, including commercial preparations thereof, or may readily be prepared from these
AP/P/ 9 4 / 0 0 7 9 6 ο
©
5 compounds by known methods. These and other methods are described in further detail in the description and examples below.
Thus, in general, the majority of the quinazoline products (formula I above) can be prepared by the cyclization of the appropriately substituted 2-aminobenzonitrile with chloroformamidine hydrochloride in diglyme, as taught by Harris et al, [J. Med. Chem., 33. 434-444 (1990)] and as further shown in Step 1 of Example 1, below. The starting 2-aminobenzonitriles are also generally available commercially, but may be prepared in accordance with the processes taught in each of Examples 2, 6, and 20-26. In these examples, the desired 2-aminobenzonitrile starting materials substituted with halogen may be prepared by the reaction of either 2aminobenzonitrile, 2-amino-5-chlorobenzonitrile, or 2-amino-6chlorobenzonitrile with 1 or 2 equivalents of N-bromosuccinimide or 1 equivalent of N-chlorosuccinimide in Ν,Ν-dimethylformamide.
Intermediates prepared by this method include the following benzonitriles:
Ο 20
Ο wherein, alternatively,
X and Z are Br;
X is Br;
X is Cl, and Z is Br;
X and Z are Cl;
W is Cl, and X is Br;
Xis Br, and Z is Cl; or W is Cl, and X and Z are Br;
with the proviso that unless otherwise specified, W, X, Y, and Z are hydrogen.
The halogenated 2-aminobenzonitrile intermediates thus prepared may then be either reacted to prepare the quinazolines (I) as previously c
©
C
Ο
C 20 ©
C 20
Ο
AP . Ο Ο 5 Ο 7 described, or used to prepare other substituted 2-aminobenzonitrile intermediates, as described below.
For example, 2-amino-5-bromo-6-chlorobenzonitrile, or 2-amino3,5-dibromobenzonitrile, can be further reacted with 1 or 2 equivalents of an optionally substituted-phenylboronic acid in the presence of tetrakis(triphenylphosphine)palladium(0) in aqueous sodium carbonate and toluene to form more complex substituted 2-aminobenzonitrile intermediates (B), as listed below. Substituted 2-aminobenzonitrile intermediates (B) prepared in this manner include, for example, 2-amino-6chloro-5-(5-chloro-2-methoxyphenyl)benzonitrile and 2-amino-6-chloro-5(3,5-dichlorophenyl)benzonitrile. These optionally substitutedphenylboronic acid intermediates are commercially available, or may be prepared by the method of Thompson and Gaudino [JOC., 49. 5237-5243 (1984)]. Step D of Example 1, Steps B-D of Example 2, and Step A of Example 5 provide detailed descriptions of how these reactions may be conducted.
Intermediates prepared by this foregoing method include those of the formula:
AP/P/ 94/00796 wherein Y is hydrogen and W, X and Z are as defined in the following table:
X z
H | Phenyl | Phenyl | |
H | Phenyl | H | |
H | a | Pbenyl | |
H | Phenyl | a | |
a | Phenyl | H | |
a | Phenyl | Phenyl | |
X. | LJ | ||
Π | |||
a | H | ||
a | a | H | |
a | XL, | XC | H |
a | H | ||
a | LAzH, /*1 | H | |
u | XU | V u | |
Π H | χΓ CP. | Π H | |
a | χΓ CF, | vr3 | H |
χΓ | j | χΓ | H |
cf3 | CF, | ||
a | 00 | H |
Alternatively, 2-aminobenzonrtrile intermediates substituted with alkyl may be prepared by the method of Harris et al., J. Med. Chem., 33.
AP.00507
434-444 (1990) by the transfer hydrogenation of the alkyl-substituted 2nitrobenzonitrile in the presence of 10% palladium on carbon in cyclohexene and ethanol, yielding the corresponding alkyl-substituted 2aminobenzonitrile, for example 6-methyl-2-aminobenzonitrile. The thus5 prepared 6-methyl-2-aminobenzonitrile may then be brominated with Nbromosuccinimide in Ν,Ν-dimethylformamide, yielding 2-amino-5-bromo-6methylbenzonitrile, which in turn can be reacted with 1 equivalent of a substituted-phenylboronic acid, as described above, affording the corresponding 2-amino-5-(substituted-phenyl)-6-methylbenzonitrile, for
0 example, 2-amino-5-(3,5-di(trifluoromethyl)phenyl]-6-methylbenzonitrile. Steps B-D of Example 1 provide detailed descriptions of how these intermediates may be prepared.
Intermediates prepared by these latter methods include those having the formula:
wherein Y and Z are hydrogen, and W and X are as follows:
AP/P/ 9 4/ 0 0 7 9 6
-CH3 | cf3 |
-CH3 | 'O-CtCHjb |
-CH3 | XT’ |
-CH3 | vCH5 ch3 |
-CH3 | Phenyl |
Other intermediates, and quinazoline products falling within formula (I) above may then be prepared from the foregoing or similar compounds by known methods.
For example, the 2-aminobenzonitrile intermediate, 2-amino-5-(2phenylethyl)benzonitrile, may be prepared using the method of Taylor and Ray [JOC., 52. 3997-4000 (1987)], by the palladium-catalyzed coupling of 2-amino-5-bromobenzonitrile with phenylacetylene, yielding 2-amino-5-(21 0 phenylethynyljbenzonitrile. The thus-prepared ethynyl compound can then be hydrogenated in the presence of 10% palladium on carbon, yielding 2amino-5-(2-phenylethyl)benzonitrile. Steps B and C of Example 6 provide a detailed description of how these reactions are conducted.
Other 2-aminobenzonitrile intermediates substituted with a sulfur1 5 bridging moiety, for example, naphth-2-ylthio, may be prepared by the method of Ashton and Hynes [J. Med. Chem., 16. 1233-1237 (1973)] by the alkylation of an appropriate arylthiol with a halogenated 2nitrobenzonitrile in the presence of potassium carbonate, yielding for example 2-nitro-5-(naphth-2-ylthio)benzonitrile. Reduction of the nitro
0 group with stannous chloride dihydrate affords the corresponding 2aminobenzonitrile intermediates. Examples 7 and 9 provide detailed descriptions of how these reactions are conducted.
A number of the quinazolines (I), or modifications thereof, may be further reacted to obtain other quinazoline derivatives falling within the
5 scope of formula I above. For example, 2,4,6-triamino-5-methylquinazoline is prepared in a step-wise manner by the nitration of 2-chloro6-methylbenzonitrile, yielding the corresponding 2-chloro-6-methyl-5nitrobenzonitrile. The 5-nitro compound may in turn be cyciyzed with guanidine carbonate in 2-ethoxyethanoi, affording 2,4-diamino-5-methyl-63 0 nftroquinazoline. These two steps of the synthesis are described in detail in Example 12. The 6-nitroquinazoline can be reduced to the corresponding 2,4,6-triamino-5-methyiquinazoline by hydrogenation in the presence of 10% palladium on carbon. Example 13 describes in detail this step in the reaction sequence.
5 In a similar manner 2,4,6-triaminoquinazoline and 2,4.6-triamino-5chloroquinazoline can be prepared. This is accomplished by the nitration
AP. Ο Ο 5 Ο 7 of, for example 2,4-diamino-5-chloroquinazoline (above) with 90% nitric acid and sulfuric acid, yielding the corresponding 2,4-diamino-5-chloro-6nitroquinazoline. The 6-nitroquinazoline is in turn reduced by either hydrogenation in the presence of 10% palladium on carbon or by treatment with stannous chloride dihydrate, affording the corresponding 2,4,6-triaminoquinazoline. Steps A and B of Example 15 describe in detail these two steps in the reaction sequence.
The 2,4,6-triaminoquinazoline derivatives described above may then optionally be treated with 2N hydrochloric acid, sodium nitrite,
0 potassium cyanide, and copper(ll) sulfate pentahydrate in water, affording C the corresponding 2,4-diamino-6-cyanoquinazoline, for example, 2,4diamino-6-cyano-5-methylquinazoline. Step A of Example 14 describes in C detail this step in the reaction sequence.
The above 2,4-diamino-6-cyanoquinazoline intermediates may be 1 5 further reacted with a substituted aniline, for example, 3,4,5-trimethoxyaniline, and hydrogen in the presence of Raney nickel in water and acetic acid, affording the corresponding 2,4-diamino-6-(substitutedaminomethyl)quinazolines. Step B of Example 14 describes in detail the preparation of this class of compounds.
In a similar manner, 2,4,6-triamino-5-chloroquinazoline can be reacted with 3,4,5-trimethoxybenzaldehyde and hydrogen in the presence of Raney nickel in 2-ethoxyethanol, affording the-corresponding 2,4¢- diamino-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline. Step C of
Example 15 describes in detail the preparation of this compound. In a
Q 2 5 similar manner there may also be prepared 2,4-diamino-6-(substitutedaminomethyl)quinazolines.
A series of quinazoline analogs may be prepared from the above
2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline. This is accomplished by the reaction of 2,4-diamino-5-chloro-6-(5-chloro-23 0 methoxyphenyQquinazoline with 1M boron tribromide in methylene chloride, yielding the corresponding 2,4-diamino-5-chloro-6-(5-chloro-2hydroxyphenyl)quinazoline. The hydroxy intermediate in turn is reacted with a halogen-containing compound and potassium carbonate in Ν,Νdimethylformamide, affording the appropriately 6-(5-chloro-2-substituted3 5 phenyl)quinazoline, for example, 2,4-diamino-5-chloro-6-[5-chloro-212
Ο e
©
Ο ο 25 (pyridin-2-ylmethoxy)phenyl]quinazoline. Example 3 describes in detail the preparation of this compound.
Other like analogs of quinazoline may be prepared in a similar manner. Quinazoline derivatives containing a sulphur bridge, for example those whose preparations are taught in Examples 7 and 9, can be oxidized to the corresponding sulfinyl derivatives using the method of Oae et al., [Bull. Chem. Soc. Japan, 39, 364-366 (1966)], by the treatment of, for example, with the bromine complex of 1,4-diazabicydo(2,2,2)-octane in aqueous 70% acetic acid. Example 11 describes in detail the preparation of 2,4-diamino-6-(3,4-dichlorophenylsulfinyl)quinazoline. The corresponding sulfonyl derivatives may then be prepared by treatment of these sulfur bridged quinazolines with potassium permanganate in acetic acid and water. Examples 8 and 10 describe in detail the preparation of these compounds.
Compounds of formula (I) above, wherein X is aroyl or substituted aroyl, e.g. Compounds 149-173 of Table 1, may be prepared in a step-wise manner using methods known from the open literature. Using the method of Beletskaya et al., (Bumagin et. al., Dokl. Akad. Nauh SSSR, 320(3), 619622 (1991)) an appropriately substituted aryl iodide, for example, 2-amino5-iodo-6-methylbenzonitrile, may be carbonylated under about one atmosphere of pressure with carbon monoxide and tetramethyiammonium tetra(optionally-substituted-phenyl)borate in the presence of a catalytic amount of palladium acetate, yielding the corresponding ketone, for example, 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6-methytbenzonitrile. The ketone may then be cyclized with chloroformamidine hydrochloride in diglyme, a method previously described, affording the targeted quinazoline derivative, for example, 2,4-diamino-5-methyl-6-(4trifluoromethylphenylcarbonyl)quinazoline. Example 19, discusses in detail this reaction sequence.
Compounds where X is arylalkylcarbonylamino, e.g.. Compounds 174 and 175 of Table 1, may be prepared, by the reaction of a 2,4,6triaminoquinazoline, for example, 2,4,6-triamino-5-chloroquinazoline (Compound 24) with an appropriate arylalkylcarbonyl halide under basic conditions, or they may be obtained commercially from Dr. John B. Hynes, Dept. of Pharmaceutical Sciences, Medical University of South Carolina,
171 Ashley Avenue, Charleston, South Carolina 29425-2303.
AP. Ο Ο 5 Ο 7
EXAMPLES
The following examples, which disclose the preparation of representative compounds of this invention (Table 1), are for the purpose of illustrating known methods for the preparation of the compounds employed in the methods and formulations of this invention, including certain novel quinazoline compounds oer se (Compounds 43-45, 47-74, 106-138, 142173, and 176-222 ).
EXAMPLE 1
0 SYNTHESIS OF 2.4-DIAMINO-5-METHYL-6(3,5-DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 63)
Step A Synthesis of chloroformamidine hydrochloride as an 15 intermediate
Diethyl ether, 600 mL, was cooled in an ice-bath and saturated with about 50 grams of hydrogen chloride gas. With vigorous stirring, a solution of 26.4 grams (0.628 mole) of cyanamide in 500 mL of diethyl ether was
0 added during a 15 minute period. Upon completion of addition, the icebath was removed and the reaction mixture was allowed to stir for about 15 minutes. A i«hite, solid precipitate was collected by filtration and washed q with diethyl ether. The solid was dried under reduced pressure, yielding
50.3 grams of chloroformamidine hydrochloride.
C 25
Step B Synthesis of 2-amino-6-methylbenzonitri,e as an intermediate
A stirred solution of 13.8 grams (0.085 mole) of 2-methyl-6-nitrobenzonitrile, 28 mL of cyclohexene, and 1.5 gram of 10% palladium on
0 charcoal in 280 mL of ethanol was heated at reflux for about 3 hours. After this time, the reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to a solid residue. The solid was triturated with 50 mL of methylene chloride, and the insoluble material was collected by filtration. Upon standing, crystals formed in the
5 filtrate. The crystals were collected by filtration and were washed quickly with a minimum amount of methylene chloride. An NMR spectrum of the
AP/P/ 9 4 / 0 0 7 9 6 c
€ o' © 25 crystals, 2.3 grams, mp 125-126°C, indicated that they were sought-after product. A second crop of product, 1.8 grams, was collected from the methylene chloride-filtrate combination. The insoluble material from the trituration was dissolved in methylene chloride and methanol and passed through a pad of diatomaceous earth. The filtrate was concentrated under reduced pressure, yielding 4.5 grams of solid. The NMR spectrum of the solid indicated that it too was the sought-after product. The total yield of 2amino-6-methylbenzonitrile was about 8.6 grams.
Step C Synthesis of 2-amino-5-bromo-6-methylbenzonitrile as an intermediate
A stirred solution of 8.3 grams (0.063 mole) of 2-amino-6-methylbenzonitrile in 125 mL of N.N-dimethyiformamide was cooled in an ice bath, and a solution of 11.2 grams (0.063 mole) of N-bromosuccinimide in 125 mL of Ν,Ν-dimethylformamide was added dropwise during a 30 minute period, while maintaining the reaction mixture temperature at about 1525°C. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, the reaction mixture was poured into 1 liter of aqueous 3N sodium hydroxide. The mixture was then diluted to a volume of about 1700 mL with distilled water. A solid precipitate was collected by filtration and dried under reduced pressure, yielding 12.3 grams of 2-amino-5-bromo-6-methylbenzonitrile, mp 111-113°C. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-amino-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]benzonrtrile as an intermediate
A stirred solution of 1.7 grams (0.008 mole) of 2-amino-5-bromo-6methylbenzonitrile, 3.2 grams (0.012 mole) of 3,5-di(trifluoromethyl)phenylboronic acid, 4.3 grams (0.031 mole) of potassium carbonate and 0.3 mL of tetrakis(triphenylphosphine)paJladium(0) in 150 mL of toluene was heated at 90°C for about 20 hours. After this time, the reaction mixture was stirred with 100 mL of water, and the organic layer was separated.
The organic layer was concentrated under reduced pressure to a residue.
AP · θ θ 5 Ο 7
The residue was subjected to column chromatography on silica gel, using 30/65/5 and 20/60/20 methylene chloride / petroleum ether / ethyl acetate as eluants. The product-containing fractions were combined and concentrated under reduced pressure, yielding about 1.0 gram of 2-amino5 6-methyl-5-[3,5-di(trifluoromethyf)phenyl]benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-6-methyl-5-[3,5-di(trifluoromethly)phenyljquinazoline (Compound 63)
A stirred mixture of 0.9 gram (0.003 mole) of 2-amino-6-methyl-5(3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.3 gram (0.003 mole) of chloroformamidine hydrochloride (prepared in Step A of this Example) in 11 mL of diglyme was gradually warmed to 165°C during a 1.5 hour period
5 The heterogeneous mixture was maintained at 165°C for about 4.5 hours.
After this time, the reaction mixture was cooled and diluted with 200 mL of diethyl ether. The resultant precipitate, which was the hydrochloride salt of the sought-after product, was collected by filtration. The hydrochloride salt was recrystallized from n-propanol and water. The solid was converted to
0 the free base by cooling it in an ice-water bath and stirring it with 30 mL of concentrated ammonium hydroxide during a one hour period. The resultant solid was collected by filtration, yielding 0.4 gram of 2,4-diamino6-methyl-5-[3,5-di(trifluoromethyl)phenyl]quinazoline. mp 222-225°C. The NMR spectrum was consistent with the proposed structure.
NOTE: The compound of Example 1 was prepared by the method of Harris et al, {J. Med. Chem., 23,434-444 (1990)]
EXAMPLE 2
0 SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-(5-CHLORO-2METHOXYPHENYL)QUINAZOLINE (COMPOUND 66)
Step A Synthesis of 2-amino-5-bromo-6-chlorobenzonitrile as an 3 5 intermediate
C
Q o
o 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 18.0 grams (0.010 mole) of N-bromosuccinimide, and 15.2 grams (0.010 mole) of 2-amino-6-chlorobenzonitrile in 200 mL of Ν,Ν-dimethylformamide. The yield of 2-amino-5-bromo-6-chlorobenzonitrile was 22.5 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 3-bromo-4-methoxychlorobenzene as an intermediate
A rapidly stirred solution of 15.5 grams (0.074 mole) of 2-bromo-4chlorophenol, 20.0 grams (0.145 mole) of anhydrous powdered potassium carbonate, and 10 mL (0.106 mole) of dimethyl sulfate in 150 mL of acetone was heated at reflux for about 18 hours. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was partitioned between 100 mL each of water and methylene chloride. The organic layer was removed and washed with an aqueous solution saturated with sodium chloride. The organic layer was then dried with magnesium sulfate and filtered. The filtrate was passed through a short column of silica gel. Elution was accomplished with 500 mL of methylene chloride. The eluate was concentrated under reduced pressure, yielding 16.3 grams of 3-bromo-4-methoxychlorobenzene. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 5-chloro-2-methoxyphenylboronic add as an intermediate
A stirred solution of 5.8 grams (0.026 mole) of 3-bromo-4methoxychlorobenzene in 150 mL of tetrahydrofuran was cooled to -80°C, and 11.5 mL of n-butyllithium in hexanes (2.5 Molar - 0.029 mole) was added dropwise during a 15 minute period, while maintaining the reaction mixture temperature at about -70°C. The initial reaction was very exothermic, which required cooling the reaction mixture to about -100°C. Upon completion of the addition, the reaction mixture was stirred at -80°C for 15 minutes. After this time, 17.5 mL (0.076 mole) triisopropyl borate was added during a 1 minute period. The reaction mixture was then allowed to
AP .0 0 5 0 7
7 warm slowly to ambient temperature during a 3 hour period, where it was stirred for an additional 1 hour. After this time, the reaction mixture was concentrated under reduced pressure to a volume of about 50 mL. The concentrate was then poured into 500 mL of ice-water. The mixture was then made acidic with about 26 mL of aqueous 2N hydrochloric acid. The mixture was then filtered to collect a solid, which was dried, yielding 3.9 grams of 5-chloro-2-methoxyphenylboronic acid. The NMR spectrum was consistent with the proposed structure.
C
Ο • / c
ο 25
NOTE: A modification of the method of Thompson and Gaudino was used to prepare 5-chloro-2-methoxyphenylboronic acid, as shown above in Step C. [JOC., 43, 5237-5243 (1984)]
Step D Synthesis of 2-amino-6-chloro-5-(5-chloro-2-methoxyphenyf)benzonitrile as an intermediate
A stirred mixture of 5.7 grams (0.020 mole) of 5-chloro-2-methoxyphenylboronic acid, 3.3 grams (0.014 mole) of 2-amino-5-bromo-6-chlorobenzonitrile (prepared in Step A of this Example), 21 mL of aqueous 2M sodium carbonate, and 0.15 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O) in 50 mL of toluene was heated at reflux for about 17 hours. After this time, 50 mL of ethyl acetate was added to the reaction mixture.
The organic layer was separated and washed with 50 mL of water and then with 50 mL of an aqueous solution saturated with sodium chloride. The organic layer was then dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 3.8 grams of 2-amino-6-chloro-5-(5-chloro-2-methoxyphenyl)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline (Compound 66)
AP/P/ 94/00796 ,8
This compound was prepared in a manner analogous to that of Step E of Example 1, using 3.8 grams (0.013 mole) of 2-amino-6-chloro-5-(5chloro-2-methoxyphenyl)benzonitrile and 1.8 grams (0.016 mole) of chloroformamidine hydrochloride in 13 mL of diglyme. The yield of 2,45 diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline was 2.8 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 3
SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-[5-CHLORO-2-(PYRIDIN-210 YLMETHOXYJPHENYLJQUINAZOLINE (COMPOUND 73) c
Step A Synthesis of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline (Compound 65) as an intermediate
A solution of 2.8 grams (0.084 mole) of 2,4-diamino-5-chloro-6-(5chloro-2-methoxyphenyl)quinazoline (prepared in Example 2) in 300 mL of methylene chloride was stirred, and 35 mL of 1.0M boron tribromide in methylene chloride was added. Upon completion of addition, the reaction
0 mixture was stirred at ambient temperature for about 21 hours. Thin layer chromatographic analysis of the reaction mixture indicated that the reaction was not complete. The reaction mixture was heated at reflux for about 6
C hours, then it was allowed to cool to ambient temperature where it was stirred for about 60 hours. After this time, the reaction mixture was poured c 2 5 into 500 mL of ice containing 100 mL of concentrated ammonium hydroxide. The mixture was filtered to collect a solid. The solid was washed with water and dried at 70°C under reduced pressure, yielding 2.4 grams of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline. The NMR spectrum was consistent with the proposed structure
Step B Synthesis of 2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2-ylmethoxy)phenyl]quinazoline (Compound 73)
Under a nitrogen atmosphere, a stirred solution of 0.5 gram (0.002
5 mole) of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline,
0.3 gram (0.002 mole) of pyridin-2-ylmethyl chloride hydrochloride, and 0.5
AP. Ο Ο 5 Ο 7 gram (0.004 mole) of potassium carbonate in 5 mL of Ν,Ν-dimethylformamide was heated at 60°C for about 24 hours. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was taken up in 100 mL of water and was stirred for about 2 hours. The resultant solid was collected by filtration, yielding 0.6 gram of
2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2-ylmethoxy)phenyl]quinazoline. The NMR spectrum was consistent with the proposed structure.
ς 10 EXAMPLE 4
SYNTHESIS OF 2.4-DIAMINO-6-BROMO-5-CHLOROQUINAZOLINE
Q. (COMPOUND 20)
This compound was prepared in a manner analogous to that of Step 15 E of Example 1, using 2.4 grams (0.010 mole) of 2-amino-5-bromo-6chlorobenzonitrile (prepared as in Step A of Example 2) and 1.4 grams (0.012 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4-diamino-6-bromo-5-chloroquinazoline was 2.4 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 5
SYNTHESIS OF 2.4-DIAMINO-5-0HLORb-6-(3,5, DICHLOROPHENYLJQUINAZOLINE (COMPOUND 51)
O 25
Step A Synthesis of 2-amino-6-chloro-5-(3.5-dichlorophenyl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step 3 0 D of Example 1, using 2.3 grams (0.010 mole) of 2-amino-5-bromo-6chlorobenzonitrile (prepared as in Step A of Example 2), 2.9 grams (0.015 mole) of 3,5-dichlorophenylboronic acid, 0.1 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0). and 30 mL of aqueous 2M sodium carbonate in 75 mL of toluene. The solid product was '
5 recrystallized from toluene, yielding 1.9 grams of 2-amino-6-chloro-5-(3,596/90 /V6 'd/dV 10 <
c
Ο 25 dichlorophenyl)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2,4-diamino-5-chloro-6-(3,5-dichlorophenyl)quinazoline (Compound 51)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.5 grams (0.005 mole) of 2-amino-6-chloro-5-(3,5dichlorophenyl)benzonitrile and 0.7 gram (0.006 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The solid was recrystallized from methanol, yielding 0.5 gram of 2,4-diamino-5-chloro-6-(3,5-dichlorophenyl)quinazoiine. The NMR spectrum was consistent with the proposed structure; however, methanol was present in the sample.
EXAMPLE 6
SYNTHESIS OF 2,4-DIAMINO-6-(2-PHENYLETHYL)QUINAZOLINE (COMPOUND 79)
Step A Synthesis of 2-amino-5-bromobenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 6.0 grams (0.051 mole) of 2-amihobenzonitrile and 9.0 grams (0.051 mole) of N-bromosucdnimide in 75 mL of N.N-dimethylformamide. The yield of 2-amino-5-bromobenzonitrile was 8.6 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(2-phenylethynyl)benzonitriie as an intermediate
A solution of 3.00 grams (0.015 mole) of 2-amino-5-bromobenzonitrile and 2.3 mL (0.021 mole) of phenyfacetylene in 50 mL of acetonitrile was stirred, and 10.6 mL of triethylamine, 0.13 gram of copper iodide, and 0.29 gram of bis(triphenylphosphine)palladium(ll) chloride were added in order. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, thin layer chromatographic (TLC) analysis of the reaction mixture indicated that no
AP . Ο Ο 5 Ο 7 reaction had taken place. The reaction mixture was warmed to 70°C, where it was stirred for about 7.5 hours. An additional 0.38 gram of phenylacetylene was added, and the reaction mixture was warmed to reflux temperature where it was stirred during about an additional 16.5 hour period. After this time, TLC analysis of the reaction mixture indicated that it contained about a 1 to 1 mixture of starting bromobenzonitrile and product. An additional 5.0 mL of triethylamine and 0.09 gram of bis(triphenylphosphine)palladium(ll) chloride catalyst was added to the reaction mixture, and the heating at reflux was continued during an
0 additional 24 hour period. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was dissolved in ethyl acetate, and the solution was washed with 50 mL of
O aqueous, dilute hydrochloric acid. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 15/10/75 tetrahydrofuran / methylene chloride / petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.85 gram of 2-amino-5-(2-phenylethynyl)benzonitrile. The NMR
0 spectrum was consistent with the proposed structure.
NOTE: The method of Taylor and Ray was used to prepare 2-amino-5-(2phenylethynyl)benzonitrile, as shown above in Step B.
[JOC., 52, 3997-4000 (1987)]
Step C Synthesis of 2-amino-5-(2-phenylethyl)benzonitrile as an intermediate
A solution of 0.85 gram (0.004 mole) of 2-amino-5-(2-phenyl3 0 ethynyl)benzonitrile in 150 mL of ethanol was prepared, and 0.2 gram (catalyst) of 10% palladium on carbon was added. The mixture was then hydrogenated using a Parr hydrogenator. Upon completion of the uptake of the theoretical amount of hydrogen, the reaction mixture was filtered and concentrated under reduced pressure to a residue. The residue was dried
5 under reduced pressure, yielding 0.74 gram of 2-amino-5-(2-phenylethyl)AP/P/ 94/00796 benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2,4-diamino-6-(2-phenylethyl)quinazoline 5 (Compound 79)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 0.74 gram (0.003 mole) of 2-amino-5-(2-phenylethyl)benzonitrile and 0.41 gram (0.004 mole) of chloroformamidine
0 hydrochloride in 11 mL of diglyme. The yield of 2,4-diamino-6-(2phenylethyl)quinazoline was 0.66 gram, mp 178-180°C, si. decomp. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 7
5 SYNTHESIS OF 2,4-DIAMINO-6-(NAPHTH-2-YLTHIO)QUINAZOLINE (COMPOUND 88)
Step A Synthesis of 2-nitro-5-(naphth-2-ylthio)benzonitrile as an intermediate
A stirred solution of 10.0 grams (0.055 mole) of 5-chloro-2nitrobenzonitrile and 8.8 grams (0.055 mole) of 2-naphthalenethiol in 80 mL of N.N-dimethylformamide was cooled to 0°C, and 7.6 grams (0.055 mole) of potassium carbonate was added. Upon completion of addition,
5 the reaction mixture was stirred at 0°C for 1 hour. Thin layer chromatographic (TLC) analysis of the reaction mixture after this time indicated that the reaction had not gone to completion. The reaction mixture was then allowed to warm to ambient temperature, where it was stirred for about 18 hours. The reaction mixture was stirred with 80 mL of pyridine and then
0 was diluted with water until a solid precipitate formed. The solid was collected by filtration and was washed in turn with an aqueous solution of 10% pyridine, water, an aqueous solution of 1% hydrochloric acid, and finally with water. The solid was then dissolved in ethyl acetate and dried with magnesium sulfate. The mixture was filtered, and the filtrate was
5 concentrated under reduced pressure to a residual solid. The solid was subjected to column chromatography on silica gel. Elution was
AP . 0 0 5 0 7 r
C c
O 25 accomplished with 10% ethyl acetate in heptane. The product-containing fractions were combined and concentrated under reduced pressure, yielding 13.5 grams of 2-nitro-5-(naphth-2-ylthio)benzonitrile. A small sample was recrystallized from ethyl acetate / hexane, mp 139-140°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(naphth-2-ylthio)benzonitrile as an intermediate
A stirred solution of 13.0 grams (0.042 mole) of 2-nitro-5-(naphth-2ylthio)benzonitrile in 200 mL of diglyme was cooled to 0°C, and a solution of 30.3 grams (0.134 mole) of stannous chloride dihydrate in 91 mL of concentrated hydrochloric acid was added. Upon completion of addition, the reaction mixture was allowed to warm to ambient temperature, where it was stirred during a 2 hour period. After this time, the reaction mixture was poured, with stirring, into a mixture of 260 grams of aqueous 50% potassium hydroxide in 300 grams of ice. An oily material, which dropped out of the solution, ultimately solidified. The solid was collected by filtration and was washed with water. The solid was dissolved in methylene chloride and was dried with magnesium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure, yielding 12.0 grams of 2-amino-5-(naphth-2-ylthio)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-6-(naphth-2-ylthio)quinazoline (Compound 88)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 12.0 grams (0.043 mole) of 2-amino-5-(naphth-2ylthio)benzonitrile and 5.5 grams (0.048 mole) of chloroformamidine hydrochloride in 25 mL of diglyme. The yield of 2,4-diamino-6-(naphth-2ylthio)quinazoline was 12.7 grams. The NMR spectrum was consistent with the proposed structure.
NOTE: The compound of Example 7 was prepared by the method of Ashton and Hynes. [J. Med. Chem., 1233-1237 (1973)]
AP/P/ 9 4/ 0 0 7 9 6
EXAMPLE 8
SYNTHESIS OF 2,4-DIAMINO-6-(NAPHTH-2-YLSULFONYL)QUINAZOLINE (COMPOUND 90)
A solution of 2.0 grams (0.006 mole) of 2,4-diamino-6-(naphth-2ylthio)quinazoline (prepared in Example 7) in 80 mL of acetic acid was stirred, and a solution of 2.0 grams (0.013 mole) of potassium
0 permanganate in 75 mL of water was added dropwise during a 1 hour C . period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 18 hours. After this time, the reaction mixture was filtered through diatomaceous earth. The filtrate was made basic by adding an excess amount of concentrated ammonium hydroxide.
5 The resultant precipitate was collected by filtration and was washed in turn with water, methanol, and acetone. The precipitate was stirred in hot Ν,Νdimethylformamide and treated with decolorizing carbon. The mixture was filtered hot, and the filtrate was set aside. The residue collected by the filtration was again stirred with hot Ν,Ν-dimethylformamide and filtered.
0 The two filtrates were combined and poured into 500 grams of ice. The resultant solid was collected by filtration, yielding 0.9 gram of 2,4-diamino6-{naphth-2-ylsulfonyl)quinazoline, mp 300-302°C. The NMR spectrum * was consistent with the proposed structure, i
5 EXAMPLE 9
O SYNTHESIS OF 2,4-DIAMINO-6-(3,4DICHLOROPHENYLTHIO)QUINAZOLINE (COMPOUND 80)
0 Step A Synthesis of 2-nitro-5-(3,4-dichlorophenylthio)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step A of Example 7, using 10.1 grams (0.006 mole) of 5-chloro-2-nitrobenzo3 5 nitrile, 9.9 grams (0.006 mole) of 3,4-dichlorobenzenethiol, 7.7 grams (0.006 mole) of potassium carbonate in 80 mL of Ν,Ν-dimethylformamide.
AP. Ο Ο 5 Ο 7
The yield oi 2-nitro-5-(3,4-dichlorophenylthio)benzonitrile was 15.9 grams, mp 136-138°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(3,4-dichlorophenylthio)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 7, using 15.9 grams (0.049 mole) of 2-nitro-5-(3,4-dichloro1 0 phenylthio)benzonitrile, 34.6 grams (0.153 mole) of stannous chloride dihydrate, and 100 mL of concentrated hydrochloric acid in 245 mL of diglyme. The yield of 2-amino-5-(3,4-dichlorophenylthio)benzonitrile was ( 15.2 grams, mp 126-128°C. The NMR spectrum was consistent with the proposed structure.
5
Step C Synthesis of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline (Compound 80)
This compound was prepared in a manner analogous to that of Step
E of Example 1, using 14.7 grams (0.050 mole) of 2-amino-5-(2,4-dichlorophenylthio)benzonitrile and 6.3 grams (0.055 mole) of chloroformamidine hydrochloride in 30 mL of diglyme. The yield of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline was 12.2 grams, mp 232-234°C. The NMR spectrum was consistent with the proposed structure.
c 25 v EXAMPLE 10
SYNTHESIS OF 2,4-DIAMINO-6-(3,4-DICHLOROPHENYLSULFONYLJQUINAZOLINE (COMPOUND 82)
This compound was prepared in a manner analogous to that of Example 8, using 2.0 grams (0.006 mole) of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline and 1.9 grams (0.012 mole) of potassium permanganate in 60 mL of acetic acid and 75 mL of water. The yield of 2,43 5 diamino-6-(3,4-dichlorophenylsulfonyl)quinazoline was 0.6 gram, mp 286289°C. The NMR spectrum was consistent with the proposed structure.
AP/P/ 94/00796
EXAMPLE 11
SYNTHESIS OF 2,4-DIAMINO-5-(3,4-DICHLOROPHENYLSULFINYL)QUINAZOLINE (COMPOUND 81)
Step A Synthesis of the bromine complex of 1,4-diazabicyclo(2,2,2)octane as an intermediate
0 A stirred solution of 2.2 grams (0.02 mole) of 1,4-diazabicyclo< (2,2,2)octane in 10 mL of carbon tetrachloride was warmed to 40°C, and a solution of 3.2 grams (0.02 mole) of bromine in 15 mL of carbon Q tetrachloride was added dropwise. The resultant precipitate was collected by filtration, washed with carbon tetrachloride, and air-dried, yielding 5.0
5 grams of the bromine complex of 1,4-diazabicyclo(2,2,2)octane.
NOTE: The method of Oae et al. was used to prepare the bromine complex of 1,4-diazabicyclo(2,2,2)octane, as shown above in Step A.
[Bull. Chem. Soc. Japan, 39, 364-366 (1966)]
Step B Synthesis of 2,4-diamino-6-(3,4-dichlorophenylsulfinyl)quinazoline (Compound 81)
A suspension of 5.0 grams (0.011 mole) of the bromine complex of
5 1,4-diazabicyclo(2,2,2)octane in 200 mL of aqueous 70% acetic acid was 'stirred, and 3.4 grams (0.01 mole) of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline was added portionwise during about a 1 hour period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, the reaction
0 mixture was neutralized with concentrated ammonium hydroxide. The resultant solid was collected by filtration and triturated with methanol. The solid was collected by filtration and dried, yielding 2,4-diamino-6-(3,4dichlorophenylsulfinyl)quinazoline, mp 200°C, dec. The NMR spectrum was consistent with the proposed structure.
AP. Ο Ο 5 Ο 7
EXAMPLE 12
SYNTHESIS OF 2.4-DIAMINO-5-METHYL-6-NITROQUINAZOLINE (COMPOUND 30)
Step A Synthesis of 2-chloro-6-methyl-5-nitrobenzonitrile as an intermediate
Under a nitrogen atmosphere, a stirred solution of aqueous 90% nitric acid was cooled to -35°C, and 40.0 grams (0.264 mole) of 2-chloro-61 0 methylbenzonitrile was added in one portion. The reaction mixture was then allowed to warm to ambient temperature, where it was stirred for about 18 hours. After this time, the reaction mixture was poured into 3000 mL of ice-water. After the ice melted, the resultant solid was collected by filtration and dried. The NMR spectrum of the solid indicated that it was about 75%
5 pure product. The solid was recrystallized twice from methanol, yielding 13.9 grams of 2-chloro-6-methyl-5-nitrobenzonitrile, mp 85.5-87.5°C. The NMR spectrum was consistent with the proposed structure. The filtrates from the recrystallizations were combined and concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 10% ethyl acetate in petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding an additional 20.4 grams of 2-chloro-6-methyl-5-nitrobenzonitrile, mp 87.589.5°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2,4-diamino-6-methyl-5-nitroquinazoline (Compound 30)
AP/P; 9 4/ 0 0 7 9 6
Under a nitrogen atmosphere, a stirred solution 29.5 grams (0.150 3 0 mole) of 2-chloro-6-methyl-5-nitrobenzonitrile and 54.0 grams (0.300 mole) of guanidine carbonate in 1500 mL of 2-ethoxyethanol was heated at reflux during a 3.5 hour period. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was stirred with 300 mL of water, and the resultant solid was collected by
5 filtration. The solid was washed with 50 mL of water and dried under reduced pressure, yielding 27.2 grams of 2,4-diamino-5-methyl-628' nitroquinazoline. The NMR spectrum was consistent with the proposed structure. The reaction was repeated again.
EXAMPLE 13
SYNTHESIS OF 2,4,6-TRIAMINO-5-METHYLQUINAZOLINE (COMPOUND 32)
A mixture of 5.0 grams (0.023 mole) of 2,4-diamino-5-methyl-6nitroquinazoline (prepared in Example 12) and 0.5 gram (catalyst) of 10%
0 palladium on carbon in 200 mL of ethanol was hydrogenated at 45-50°C C using a Parr hydrogenator. The theoretical uptake of hydrogen required about 2.5 hours. The hydrogenation was repeated twice more, using 15.0 grams (0.068 mole) and 11.0 grams (0.050 mole), respectively, of 2,4diamino-5-methyl-6-nitroquinazoline. The total yield of 2,4,6-triamino-51 5 methylquinazoline was 19.5 grams. The NMR spectra were consistent with the proposed structure.
EXAMPLE 14
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[(3,4,52 0 TRIMETHOXYPHENYLAMINO)METHYL]QUINAZOLINE (COMPOUND 93) ♦
f Step A Synthesis of 2,4-diamino-6-cyano-5-methylquinazoline as an intermediate (7* 25
Under a nitrogen atmosphere, a stirred solution of 2.5 grams (0.013 mole) of 2,4,6-triamino-5-methylquinazoline (prepared in Example 13) and 25 mL of 2N hydrochloric acid (0.050 mole) was cooled to 5°C, and a solution of 1.1 grams (0.016 mole) of sodium nitrite in 4 mL of water was
0 added dropwise. Upon completion of addition, the reaction mixture was stirred at 5°C during a 10 minute period. In a separate reaction vessel, a stirred solution of 14.7 grams (0.225 mole) of potassium cyanide in 70 mL of water was cooled to 5°C, and a solution of 1.4 grams (0.056 mole) of copper(ll) sulfate pentahydrate in 100 mL of water was added dropwise.
5 To this solution was added, portionwise, the reaction mixture containing the quinazoline diazonium salt prepared above. Upon completion of addition,
AP. ο ο 5 ο 7
Γ (
C ρ 25 the reaction mixture was allowed to warm to ambient temperature as it stirred during a 2 hour period. After this time, the reaction mixture was diluted with 60 mL of aqueous 50% potassium carbonate and was extracted with four 700 mL portions of tetrahydrofuran. The combined extracts were acidified with 50 mL of acetic acid, and the mixture was concentrated under reduced pressure to a residual solid. The solid was subjected twice to column chromatography on silica gel. Elution was accomplished in each case with 20% N.N-dimethylformamide in ethyl acetate. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.1 grams of 2,4-diamino-6-cyano5-methylquinazoline. The NMR spectrum was consistent with the proposed structure; however, it showed that the product was in the form of the acetate salt.
Step B Synthesis of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylaminojmethyljquinazoline (Compound 93)
A mixture of 1.1 grams (0.005 mole) of 2,4-diamino-6-cyano-5methylquinazoline, 4.6 grams (0.025 mole) 3,4,5-trimethoxyaniline and 2.0 grams (catalyst) of Raney nickel (50% slurry in water) in 30 mL of water and 70 mL of acetic acid was hydrogenated at 50 psi of hydrogen for 6 hours using a Parr hydrogenator. After this time the reaction mixture was filtered. The filter cake was slurried with a boiling mixture of 15 mL of water and 35 mL of acetic acid and was then filtered. The filtrates were combined and subjected to thin layer chromatography (TLC). The TLC analysis indicated that a small amount of the starting quinazoline remained unreacted. The filtrate was combined with 1.0 gram of Raney nickel and the mixture was again hydrogenated for an additional 1.5 hours using the Parr hydrogenator. After this time the reaction mixture was filtered and concentrated under reduced pressure to a residual oil. The residual oil was subjected to column chromatography on silica gel. Elution was accomplished initially using 25% N.N-dimethylformamide in ethyl acetate and, finally 40% Ν,Ν-dimethylformamide in ethyl acetate. The productcontaining fractions were combined and concentrated under reduced pressure to a residual solid. The solid was recrystallized from water, yielding 0.5 gram of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenyl96/00/)6 /d/d! V amino)methyl]quinazoline, mp 95-210°C. The NMR analysis was consistent with the proposed structure; however, it indicated that the compound was a complex with acetic acid and water.
NOTE: The compound of Example 14 is known in the literature as Trimetrexate®, for use in treatments of certain kinds of cancers.
[J. Med. Chem., 2£, 1753-1760 (1983)]
EXAMPLE 15
SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-[(3,4,5TRIMETHOXYPHENYLMETHYL)IMINO]QUINAZOLINE
COMPOUND 91
Step A Synthesis of 2,4-diamino-5-chloro-6-nitroquinazoline as an intermediate
Nitric acid (90%), 125 mL, was stirred and cooled to -10°C, and 125 mL of 98% sulfuric acid was added dropwise. Upon completion of addition, the reaction mixture temperature was brought to 0°C, and 19.7 grams (0.10 mole) of 2,4-diamino-5-chloroquinazoline (Compound 2, prepared in a manner analogous to that of Step E of Example 1) was added. Upon completion of addition, the reaction mixture was allowed to warm to ambient temperature where it was stirred for about 18 hours. The reaction mixture was then poured into 1500 mL of ice. The resultant mixture was made basic with 700 mL of aqueous 30% ammonia, keeping the temperature below 30°C. The mixture was cooled in an ice-bath, and the resultant solid was collected by filtration. The solid was stirred with 1000 mL of tetrahydrofuran and 500 mL of water. The mixture was filtered to remove a solid. The filtrate was diluted with 500 mL of ethyl acetate and then was concentrated under reduced pressure to a solid residue. The two solids were combined, washed with ethyl acetate, and dried, yielding 22.2 grams of 2,4-diamino-5-chloro-6-nitroquinazoline. The NMR spectrum was consistent with the proposed structure.
Step B1 Synthesis of 2,4,6-triamino-5-chloroquinazoline (Compound 24) as an intermediate
AP. Ο Ο 5 Ο 7
This compound was prepared in a manner analogous to that of Example 13, using 11.0 grams (0.049 mole) of 2,4-diamino-5-chloro-6nitroquinazoline and 1.0 gram of 10% platinum on carbon in 70 mL of
2-methoxyethanol and 130 mL of ethanol, yielding 2,4,6-triamino-5chloroquinazoline.
Step C Synthesis of 2,4-diamino-5-chloro-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline (Compound 91)
C' Under a nitrogen atmosphere, a stirred solution of 3.0 grams (0.014 mole) of 2,4,6-triamino-5-chloroquinazoline and 2.9 grams (0.029 mole) of 3,4,5-trimethoxybenzaldehyde in 30 mL of ethanol was heated at reflux during a 5 hour period. After this time, the resultant slurry was mixed with
50 mL of 2-ethoxyethanol, 70 mL of ethanol, and 2.0 grams (catalyst) of
Raney nickel. The mixture was then hydrogenated at 50 psi of hydrogen during a 5 hour period using a Parr hydrogenator. The mixture was then filtered, and the filter cake was slurried with 50 mL of ethanol. The ethanol was decanted from the catalyst. The remaining solid and catalyst were
0 slurried with an additional 50 mL of ethanol which was then decanted from the catalyst. The decantates were combined with 100 mL of dioxane and 2.0 grams of Raney nickel and hydrogenated during a four hour period, as described above. The reaction mixture was then diluted with 200 mL of dioxane and heated to reflux, at which time complete solution was ~ 25 obtained. The solution was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to a solid residue. The solid was recrystallized from dioxane and water, yielding 2.4 grams of solid platelets, mp 234-235°C. The NMR spectrum indicated the solid to be 2,4-diamino5-chloro-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline.
EXAMPLE 16
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(3,5DICHLOROPHENYL)QUINAZOLINE (COMPOUND 116)
Step A Synthesis of 3,5-dichlorophenylboronic acid as an intermediate
AP/PZ 9 4 / 0 0 7 9 6
This compound was prepared in a manner analogous to that of Step C of Example 2, using 20.0 grams (0.073 mole) of 3,5-dichlorophenyl iodide, 32.0 mL of n-butyllithium (0.080 mole - 2.5M in hexanes) and 48.6 mL (0.220 mole) of triisopropyl borate. The yield of 3,5-dichlorophenylboronic acid was 6.7 grams; mp >250 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-6-methyl-5-(3,5-dichlorophenyl)1 0 benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 4.3 grams (0.024 mole) of 3,5-dichlorophenylboronic acid, 4.8 grams (0.023 mole) of 2-amino-5-bromo-6-methylbenzonitrile,
5 about 22 mL of aqueous 2M sodium carbonate, and about 0.15 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0) in 50 mL of toluene. The yield of 2-amino-6-methyl-5-(3,5-dichlorophenyl)benzonitrile was 4.4 grams, mp 182 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline (Compound 116)
This compound was prepared in a manner analogous to that of Step
E of Example 1, using 4.2 grams (0.015 mole) of 2-amino-6-methyl-5-(3,5dichlorophenyl)benzonitrile and 2.0 grams (0.017 mole) of chloroformamidine hydrochloride in about 15 mL of diglyme. The yield of 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline was 2.7 grams, mp >250 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 17
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[1-CHLORO-2-(4TRIFLUOROMETHYLPHENYL)ETHENYL]QUINAZOLINE (COMPOUND 143)
AP . 0 0 5 0 7
Step A Synthesis of 2-amino-5-iodo-6-methylbenzonitrile as an intermediate
Ο r
c c, 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 17.5 grams (0.132 mole) of 2-amino-6-methylbenzonitrile (prepared as in Step B of Example 1) and 29.8 grams (0.132 mole) of N-iodosuccinimide in 325 mL of Ν,Ν-dimethylformamide. The yield of 2amino-5-iodo-6-methylbenzonitrile was 28.5 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(trimethylsilylethynyl)-6-methylbenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 6, using 10.0 grams (0.039 mole) of 2-amino-5-iodo-6methylbenzonitrile, 8.3 mL (0.059 mole) of (trimethylsilyl)acetylene, 0.5 gram (catalyst) of bis(triphenylphosphine)palladium(ll) chloride, 0.2 gram (catalyst) of copper(l) iodide, and 21 mL (0.156 mole) of triethylamine in 75 mL of acetonitrile. The yield of 2-amino-5-(trimethylsilylethynyl)-6methylbenzonitrile was 6.6 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-amino-5-ethynyl-6-methylbenzonitrile as an intermediate
AP/P/ 9 4 / 0 0 7 9 6
A mixture of 1.4 grams (0.006 mole) of 2-amino-5-(trimethylsilylethynyl)-6-methylbenzonitrile and 0.9 gram (0.006 mole) of potassium carbonate in 50 mL of methanol was stirred at ambient temperature for one hour. The reaction mixture was then concentrated under reduced pressure to a residue. The residue was taken up in about 75 mL of water, and the solution was extracted with two 200 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 1.0 gram of 2amino-5-ethynyl-6-methylbenzonitrile. The NMR spectrum was consistent with the proposed structure. This reaction was repeated several times.
Step D Synthesis of 2-amino-6-methyl-5-[(4-trifluoromethylphenyl)ethynyl]benzonitrile as an intermediate
A solution of 3.5 grams (0.022 mole) of 2-amino-5-ethynyl-65 methylbenzonitrile, 8.4 grams (0.031 mole) of 4-trifluoromethylphenyl iodide, 10.7 grams (0.077 mole) of triethylamine, 0.5 gram (catalyst) of bis(triphenylphosphine)palladium(ll) chloride, and 0.5 gram (catalyst) of copper(l) iodide in 100 mL of acetonitrile was stirred at ambient temperature for about 18 hours. After this time the reaction mixture was
0 concentrated under reduced pressure to a residue. The residue was f' partitioned between ethyl acetate and aqueous 1N hydrochloric acid. The two-layered mixture was filtered to remove a solid. The aqueous layer and (j / the organic layer were separated, and the aqueous layer was washed with ethyl acetate. The ethyl acetate wash was combined with the organic layer,
5 and the combination was washed with an aqueous solution of 10% lithium chloride. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was triturated with methylene chloride and filtered. The filtrate was subjected to column chromatography on silica gel. Elution was
0 accomplished using methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 4.8 grams of 2-amino-6-methyl‘5-[(4-trifluoromethylphenyl)ethynyl]benzonitrile, mp 136-138 °C. The NMR spectrum was consistent with the proposed structure.
c 25
Step E Synthesis of 2,4-diamino-5-methyl-6-[1-chloro-2-(4trifluoromethylphenyl)ethenyl]quinazoline (Compound 143)
This compound was prepared in a manner analogous to that of Step
0 E of Example 1, using 2.7 grams (0.009 mole) of 2-amino-6-methyl-5-[(4trifluoromethylphenyl)ethynyl]benzonitrile and 1.2 grams (0.011 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. Upon completion of the reaction, the reaction mixture was diluted with 200 mL of diethyl ether. The resultant solid was collected by filtration, and was dissolved in a hot
5 mixture of 300 mL of water and 100 mL of n-propanol. The solution was filtered hot through a sintered glass funnel to remove some insoluble
AP.00507 material. The filtrate was then made basic with 100 mL of concentrated ammonium hydroxide. The resultant solid was collected by filtration, and dried at 60 °C under vacuum. The solid was then dissolved in a solution of 10% methanol in methylene chloride, and the solution was subjected to column chromatography on silica gel. Elution was accomplished using 10% methanol in methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.6 grams of 2,4-diamino-5-methyl-6-[1-chloro-2-(4-trifluoromethylphenyl)ethenyl]quinazoline, mp >300 °C. The NMR spectrum was
0 consistent with the proposed structure.
EXAMPLE 18
C : SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(5-CHLOROTHIEN-2YL)QUINAZOLINE (COMPOUND 146)
Step A Synthesis of (5-chlorothien-2-yl)tributyl tin as an intermediate
A stirred solution of 5.1 mL (0.046 mole) of 2-bromo-5-chloro2 0 thiophene in 200 mL of tetrahydrofuran was cooled to -85 °C, and 19.7 mL (0.049 mole) of n-butyllithium (0.049 mole - 2.5M in hexanes) was added dropwise during a 15 minute period. The reaction mixture temperature was ζ maintained at -85 °C to -80 °C throughout the addition. Upon completion of addition, the reaction mixture temperature was maintained at about -80 °C for one hour. After this time, a solution of 12.5 mL (0.046 mole) of tributyltin chloride in 50 mL of tetrahydrofuran was added to the cold reaction mixture during a 10 minute period. Upon completion of addition, the reaction mixture was stirred at -80 °C for one hour, then it was allowed to warm gradually to ambient temperature. The reaction was quenched with an
0 aqueous solution saturated with ammonium chloride, and then the reaction mixture was extracted with three 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 18.4 grams of (5-chlorothien-2-yl)tributyi tin. The NMR spectrum was consistent with the
5 proposed structure.
AP/P/ 9 4/ 0 0 7 9 6
Step B Synthesis of 2-amino-6-methyl-5-(5-chlorothien-2-yl)benzonitrile as an intermediate
A solution of 5.9 grams (0.015 mole) of (5-chlorothien-2-yl)tributyl tin 5 and 3.0 grams (0.015 mole) of 2-amino-5-iodo-6-methylbenzonitrile in 150 mL of toluene was stirred, and 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O) was added. The reaction vessel was evacuated, and then back-filled with dry nitrogen gas. This process was repeated two more times. The reaction mixture was then heated to reflux where it was
0 stirred for about 18 hours. After this time the reaction mixture was concentrated under reduced pressure to a residue. The residue was dissolved in methylene chloride, and the solution was filtered through a θ fiber-glass pad to remove the catalyst. The filtrate was subjected to column chromatography on silica gel. Elution was accomplished using methylene
5 chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 2.0 grams of 2-amino-6methyl-5-(5-chlorothien-2-yl)benzonitrile, mp 108-110 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(5-chlorothien-2yl)quinazoline (Compound 146) q This compound was prepared in a manner analogous to that of Step
E of Example 1, using 1.6 grams (0.007 mole) of 2-amino-6-methyl-5-(5& 25 chlorothien-2-yl)benzonitrile and 0.8 gram (0.008 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4-diamino-5methyl-6-(5-chlorothien-2-yl)quinazoline was 1.1 grams, mp 270-272 °C, dec. The NMR spectrum was consistent with the proposed structure.
0 EXAMPLE 19
SYNTHESIS OF 2.4-DIAMINO-5-METHYL6-(4-TRIFLUOROMETHYLPHENYLCARBONYL)QUINAZOLINE (COMPOUND 158)
5 Step A Synthesis of 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6methylbenzonitrile as an intermediate
AP.00507 r
© c
25
A mixture of 2.6 grams (0.01 mole) of 2-amino-5-iodo-6-methylbenzonitrile (prepared in Step A of Example 17), 8.3 grams (0.0125 mole) of tetramethylammonium tetra(4-trifluoromethylphenyl)borate, and 0.1 gram (0.0005 mole) of palladium(ll) acetate in 50 mL of Ν,Ν-dimethylformamide is placed in a high pressure reaction vessel. The stirring reaction mixture is then placed under 1 atmosphere of carbon monoxide gas, where it is maintained at about 60 °C for a 30 hour period. After this time, the cooled reaction mixture is removed from the reaction vessel and is filtered to remove catalyst and salts. The filtrate is concentrated under reduced pressure to a residue. The residue is partitioned between methylene chloride and water. The methylene chloride-product solution is then subjected to column chromatography on silica gel. Elution is accomplished with methylene chloride. The product-containing fractions are combined and concentrated under reduced pressure, yielding about 2.0 grams of 2amino-5-(4-trifluoromethylphenylcarbonyl)-6-methylbenzonitrile.
Step B Synthesis of 2,4-diamino-5-methyl-6-(4-trifluorophenylcarbonyl)quinazoline (Compound 158)
This compound is prepared in a manner analogous to that of Step E of Example 1, using 2.0 grams (0.009 mole) of 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6-methylbenzonitrile and 0.9 gram (0.009 mole) chloroformamidine hydrochloride in 20 mL of diglyme, yielding 2,4diamino-5-methyl-6-(4-trifluorophenylcarbonyl)quinazoline.
EXAMPLE 20
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(3-FLUORO-5TRIFLUOROMETHYLPHENYL)QUINAZOLINE (COMPOUND 188)
Step A Synthesis of 3-fluoro-5-trifluoromethylphenylboronic acid as an intermediate
A crystal of iodine and 0.5 gram (0.021 mole) of magnesium turnings were placed in a reaction vessel containing 10 mL of tetrahydrofuran. To
ΑΡ/Γ/ 9 4 / 0 0 7 9 6 1 0 ι
c c
O 25 this was added dropwise 2 mL of a solution of 5.0 grams (0.021 mole) of 3fluoro-5-trifluoromethylphenyl bromide in 65 mL of tetrahydrofuran. The Grignard formation was initiated by warming the reaction vessel to about 45 °C. The remaining 3-fluoro-5-trifluoromethylphenyl bromide tetrahydrofuran solution was added portionwise at a rate which maintained gentle reflux of the reaction mixture.
In a second reaction vessel, 40 mL of tetrahydrofuran was cooled to -78 °C, and 2.3 mL (0.021 mole) of trimethyl borate was added dropwise as the Grignard reagent of 3-fluoro-5-trifluoromethylphenyl bromide prepared above was transferred into the second reaction vessel using a cannula. The temperature of the reaction mixture was maintained below -60 °C during the additions. Upon completion of the additions, the reaction mixture was again cooled to -78 °C, where it was stirred for about 45 minutes. After this time, the reaction mixture was allowed to warm to ambient temperature. The reaction mixture was then poured into about 200 mL of water and was made acidic with aqueous 5% hydro-chloric acid. The mixture was extracted with four 100 mL portions of ethyl acetate. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 3.3 grams of 3fluoro-5-trifluoromethylphenylboronic acid, mp 167-168 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-6-methyl-5-(3-fluoro-5trifluoromethylphenyl)benzonitrile as an intermediate
Under a dry nitrogen atmosphere, 0.5 gram (0.0004 mole) of tetrakis(triphenyl-phosphine)palladium(0) was added to a stirred mixture of 2.8 grams (0.0132 mole) of 2-amino-5-bromo-6-methylbenzonitrile (prepared as in Step C of Example 1), 35 mL ol aqueous 2M sodium carbonate and 50 mL of toluene. To this was then added dropwise a solution of 3.3 grams (0.0159 mole) of 3-fluoro-5-trifluoromethylphenylboronic acid in 10 mL of ethanol. Upon completion of addition, the reaction mixture was warmed to about 80 °C, where it was stirred for seven hours. After this time the reaction mixture was poured into 200 mL of water. The mixture was then extracted with four 100 mL portions of ethyl acetate. The combined extracts were dried with magnesium sulfate and filtered. The
AP.00507 filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished with methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 4.0 grams of 2-amino-6-methyl-5-(3-fluoro-5-trifluoromethylphenyl)-.
benzonitrile, mp 96-97 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(3-fluoro-510 trifluoromethylphenylj-quinazoline (Compound 188)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 3.7 grams (0.013 mole) of 2-amino-6-methyl-5-(3fluoro-5-trifluoromethylphenylbenzonitrile and 1.7 grams (0.015 mole) of
5 chloroform-amidine hydrochloride in 25 mL of diglyme. The yield of 2,4diamino-5-methyl-6-(3-fluoro-5-trifluoromethylphenyl)quinazoline was 2.8 grams, mp 225-226 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 21
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[3-(4FLUOROPHENYL)PHENYLJQUINAZOLINE (COMPOUND 196)
5 Step A Synthesis of 3-(4-fluorophenyl)phenyl bromide as an intermediate
AP/P/ 94/00796
This compound was prepared in a manner analogous to that of Step D of Example 2, using 6.2 grams (0.044 mole) of 4-fluorophenylboronic
0 acid (commercially available), 25.0 grams (0.100 mole) of 1,3dibromobenzene, 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O), 75 mL of aqueous 2M sodium carbonate, and 75 mL of toluene. The yield of 3-(4-fluorophenyl)phenyl bromide was 7.1 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 3-(4-fluorophenyl)phenylboronic acid as an intermediate r
c
5 c· o 25
This compound was prepared in a manner analogous to that of Step C of Example 2, using 7.1 grams (0.028 mole) of 3-(4-fluorophenyl)phenyl bromide, 17 mL (0.034 mole) of n-butyllithium (2.0 M in hexanes), and 9.5 mL (0.084 mole) of trimethyl borate in 100 mL of tetrahydrofuran. The yield of 3-(4-fluorophenyl)phenylboronic acid was about 3.5 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 3.4 grams (0.016 mole) of 3-(4fluorophenyl)phenylboronic acid, 3.3 grams (0.016 mole) of 2-amino-5bromo-6-methylbenzonitrile, 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O), 50 mL of aqueous 2M sodium carbonate, and 50 mL of toluene. The yield of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzonitrile was 4.8 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2,4-diamino-5-methyl-6-[3-(4fluorophenyl)phenyl]quinazoline (Compound 196)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 2.0 grams (0.007 mole) of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzo-nitrile and 0.8 gram (0.007 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4diamino-5-methyl-6-[3-(4-fluorophenyl)phenyl]quinazoline was 0.5 gram. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 22
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[3-(4CHLOROPHENOXY)PHENYL]QUINAZOLINE (COMPOUND 205)
AP. Ο Ο 5 Ο 7
Step A Synthesis of 3-(4-chlorophenoxy)phenyl bromide as an intermediate
Under a nitrogen atmosphere, a solution of 13.6 grams (0.106 mole) 5 of 4-chlorophenol in 50 mL of diglyme was stirred, and 24.1 mL (0.106 mole) of methanolic 25% sodium methoxide was added dropwise. Upon completion of addition, the reaction mixture was heated to about 165 °C to remove methanol. After the methanol was removed, the heating was ceased, and 25.0 grams (0.106 mole) of 1,3-dibromobenzene and 1.3
0 grams of cuprous bromide were added. Upon completion of the additions, ' the reaction mixture was heated to reflux where it was stirred for about 21 hours. The reaction mixture was then cooled and filtered. The filter cake C was washed with diethyl ether, and the wash was combined with the filtrate. The combination was extracted with two 20 mL portions of aqueous 1 5 20% sodium hydroxide and then with two 75 mL portions of an aqueous solution saturated with sodium chloride. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residual oil. The oil was distilled under vacuum, yielding about 9.0 grams of 3-(4-chlorophenoxy)phenyl bromide, bp 110 °C / 0.5 mm Hg. The NMR spectrum was consistent with the proposed structure.
Q Step B Synthesis of 3-(4-chlorophenoxy)phenylboronic acid as an intermediate 25
This compound was prepared in a manner analogous to that of Step C of Example 2, using 9.0 grams (0.032 mole) of 3-(4-chlorophenoxy)phenyl bromide, 14 mL (0.035 mole) of n-butyllithium (2.5M in hexanes), and 10.4 mL (0.095 mole) of trimethyl borate in 100 mL of tetrahydrofuran.
0 The yield of 3-(4-chlorophenoxy)phenylboronic acid was about 7.6 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-amino-6-methyl-5-[3-(4-chlorophenoxy)phenyljbenzonitrile as an intermediate
AP/P/ 94/00796
This compound was prepared in a manner analogous to that of Step D of Example 2, using 7.6 grams (0.031 mole) of 3-(4chlorophenoxy)phenylboronic acid, 6.5 grams (0.031 mole) of 2-amino-5bromo-6-methylbenzonitrile, about 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0), about 30 mL of aqueous 2M sodium carbonate, and about 50 mL of toluene. The yield of 2-amino-6methyl-5-[3-(4-chlorophenoxy)-phenyl]benzonitrile was 2.0 grams. The NMR spectrum was consistent with the proposed structure.
0 Step E Synthesis of 2,4-diamino-5-methyl-6-[3-(4chlorophenoxy)phenyl]quinaz-oline (Compound 205)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.8 grams (0.005 mole) of 2-amino-6-methyl-5-[3-(41 5 chloro-phenoxy)phenyl]benzonitrile and 0.6 gram (0.005 mole) of chloroformamidine hydrochloride in about 10 mL of diglyme. The yield of
2,4-diamino-5-methyl-6-[3-(4-chlorophenoxy)phenyl]quinazoline was 0.9 gram. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 23
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(6-CHLORO-2,3-DIHYDRO2,2-DIMETHYLBENZOFURAN-4-YL)QUINAZOLINE (COMPOUND 210)
Step A Synthesis of 2-methyl-3-(3-chloro-2-cyanophenoxy)-1propene as an intermediate
A solution of 30.0 grams (0.174 mole) of 2,6-dichlorobenzonitrile and 14.7 mL (0.174 mole) of 2-methyl-2-propen-1-ol in 200 mL of dimethyl
0 sulfoxide was stirred, and 12.7 grams (0.191 mole) of 85% potassium hydroxide was added portionwise during a 5 minute period. During the addition, the reaction mixture temperature rose from 20 °C to about 35 °C. Upon completion of the addition, the reaction mixture was stirred at ambient temperature for about 18 hours. After this time the reaction mixture
5 was poured into 600 mL of water. The mixture was filtered to collect a solid. The solid was washed with water and dried under vacuum, yielding
AP.00507
33.9 grams of 2-methyl-3-(3-chloro-2-cyanophenoxy)-1-propene. The
NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 6-chloro-7-cyano-2,3-dihydro-2,25 dimethylbenzofuran as an intermediate
A stirred mixture of 33.9 grams (0.163 mole) of 2-methyl-3-(3-chloro2-cyano-phenoxy)-1-propene and 0.2 gram (0.0017 mole) of magnesium chloride was warmed to 180 °C during a one hour period, where it was
0 stirred for about six hours. The product, which sublimed to the top of the reaction vessel, was subjected to column chromatog-raphy on silica gel. Elution was accomplished using 1:1 methylene chloride and petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 25.8 grams of 6-chloro-7-cyano-2,31 5 dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step C. Synthesis of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A strirred solution of 10.0 grams (0.048 mole) of 6-chloro-7-cyano2,3-dihydro-2,2-dimethylbenzofuran 4h 200 mL of 2-methyl-2-propanol was warmed to reflux, and 9.5 grams (0.17 mole) of 85% potassium hydroxide was added in one portion. Upon completion of addition, the reaction
5 mixture was heated at reflux for about 75 minutes. The reaction mixture was then cooled and poured into 400 mL of water that was cooled in an ice bath. The resultant solid was collected by filtration and dried under vacuum, yielding 8.2 grams of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran. The NMR spectrum was consistent with the proposed
0 structure.
Step D Synthesis of 7-amino-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 5.8 grams (0.145 mole) of sodium hydroxide in 100 mL of water was cooled to 0 °C, and 7.3 grams (0.045 mole) of
AP/P/ 94/00796 bromine was added dropwise during a 5 minute period. Upon completion of addition, the mixture was stirred for 5 minutes, and an emulsion of 8.2 grams (0.036 mole) of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran in 75 mL of dioxane was added portionwise during a 15 minute period. Upon completion of addition, the reaction mixture was stirred at 0 °C for one hour. The reaction mixture was warmed to 75 °C during a two hour period, where it was stirred for 19 hours. After this time the reaction mixture was cooled and poured into 300 mL of water. The mixture was then extracted with two 200 mL portions of ethyl acetate. The combined extracts were washed with an aqueous solution saturated with sodium chloride and dried with magnesium sulfate. The mixture was filtered and concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using methylene chloride. The product containing fractions were combined and concentrated under reduced pressure, yielding 4.5 grams of 7-amino-6-chloro-2,3-dihydro-2,2dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 7-amino-4-bromo-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an. intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 4.5 grams (0.023 mole) of 7-amino-6-chloro-2,3dihydro-2,2-dimethylbenzofuran and 4.1 grams (0.023 mole) of Nbromosuccinimide in 50 mL of Ν,Ν-dimethylformamide. The yield of 7amino-4-bromo-6-chloro-2,3-dihydro-2,2-dimethylbenzofuran was 5.1 grams. The NMR spectrum was consistent with the proposed structure.
Step F Synthesis of 4-bromo-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 5.1 grams (0.018 mole) of 7-amino-4-bromo-6chloro-2,3-dihydro-2,2-dimethylbenzofuran and 25 mL of toluene in 100 mL of ethanol was cooled in an ice bath, and 2 mL (0.036 mole) of concentrated sulfuric acid was added slowly. Upon completion of addition,
AP. Ο Ο 5 Ο 7
2.0 grams (0.029 mole) of sodium nitrite was then added. The ice bath was then removed, and the reaction mixture was warmed to 75 °C, where it stirred for 30 minutes. After this time the reaction mixture was warmed to 95 °C, where it stirred for one hour. The reaction mixture was then cooled and poured into 200 mL of water. The mixture was extracted with two 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using petroleum
0 ether. The product-containing fractions were combined and concentrated f' under reduced pressure, yielding 3.6 grams of 4-bromo-6-chloro-2,3dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with C the proposed structure.
5 Step G Synthesis of 6-chloro-2,3-dihydro-2,2-dimethylbenzofuran-4ylboronic acid as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 2, using 3.6 grams (0.014 mole) of 4-bromo-6-chloro-2,320 dihydro-2,2-dimethylbenzofuran, 5.5 mL (0.014 mole) of n-butyllithium (2.5M in hexanes), and 4.7 mL (0.042 mole) of trimethyl borate in 75 mL of tetrahydrofuran. The yield of 6-chloro-2,3-dihydro-2,2-dimethylbenzofuranq 4-ylboronic acid was 3.0 grams. The NMR spectrum was consistent with the proposed structure.
© 25
Step H Synthesis of 2-amino-6-methyl-5-(6-chloro-2,3-dihydro-2,2dimethylbenzofuran-4-yl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step
0 D of Example 2, using 3.0 grams (0.013 mole) of 6-chloro-2,3-dihydro-2,2dimethyl-benzofuran-4-yl-boronic acid, 2.1 grams (0.031 mole) of 2-amino5-iodo-6-methylbenzonitrile (prepared as in Step A of Example 17), 0.12 gram (catalyst) of tetrakis(triphenylphosphine)pallad-ium(0), 10 mL of aqueous 2M sodium carbonate, and 100 mL of toluene. The yield of 23 5 amino-6-methyl-5-(6-chloro-2,3-dihydro-2,2-dimethylbenzofuran-4AP/P/ 9 4 / 0 0 7 9 6 rc c
o 25 yl)benzonitrile was 1.9 grams. The NMR spectrum was consistent with the proposed structure.
Step I Synthesis of 2,4-diamino-5-methyl-6-(6-chloro-2,3-dihydro2,2-dimethylbenzofuran-4-yl)quinazoline (Compound 210)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.7 grams (0.005 mole) of 2-amino-6-methyl-5-(6chloro-2,3-dihydro-2,2-dimethylbenzofuran-4-yl)benzonitrile and 0.8 gram (0.006 mole) of chloroformamidine hydrochloride in 15 mL of diglyme. The yield of 2,4-diamino-5-methyl-6-(6-chloro-2,3-dihydro-2,2dimethylbenzofuran-4-yl)quinazoline was 1.2 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 24
SYNTHESIS OF 2,4-DIAMINO-7-FLUORO-5-METHYL-6-[3,5DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 214)
Step A Synthesis of 5-fluoro-2-methylcarbonylamino-3methylnitrobenzene as an intermediate
Stirred acetic anhydride, 300 mL, was cooled to about 7 °C, and 25.1 grams (0.20 mole) of 4-fluoro-2-methylaniline was added dropwise during a 30 minute period. Upon completion of addition, the reaction mixture was stirred at about 10 °C for an additional 15 minutes. In a separate reaction vessel, acetyl nitrate was prepared by the dropwise addition of 14.9 mL of 90% nitric acid to 30 mL of stirred, cold (0 -15 °C) acetic anhydride during a 15 minute period. The so-prepared acetyl nitrate was cooled to about -5 °C, placed in a dropping funnel, and added dropwise during a 30 minute period to the 2-methylaniline solution. Upon completion of addition, the reaction mixture was stirred an additional 5 hours. After this time the reaction mixture was poured into 400 grams of ice. The resultant solid was collected by filtration, washed with water, and dried at 60 °C under vacuum, yielding 23.0 grams of 5-fluoro-2AP .0 0 5 0 7
Ο
C ·
Ο
Ο 25 methylcarbonylamino-3-methylnitrobenzene, mp 167-172 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 4-fluoro-2-nitro-6-methylaniline as an intermediate
A stirred solution of 22.4 grams (0.106 mole) of 5-fluoro-2methylcarbonyl-amino-3-methylnitrobenzene, 100 mL of concentrated hydrochloric acid, and 100 mL of ethanol was heated at reflux for about 17 hours. The reaction mixture was cooled and poured into 500 grams of ice. The mixture was made basic with aqueous 50% sodium hydroxide. The resultant solid was collected by filtration and was thoroughly washed with water. The solid was dried at about 60 °C under vacuum, yielding 17.0 grams of 4-fluoro-2-nitro-6-methylaniline, mp 111-113 °C. The NMR spectrum was consistent with the proposed structure. The reaction was repeated to obtain more product.
Step C Synthesis of 4-fluoro-2-nitro-6-methylphenyl iodide as an intermediate
A mixture of 4.4 grams (0.026 mole) of 4-fluoro-2-nitro-6methylaniline, 13.2 grams (0.052 mole) of iodine, and 5.5 grams (0.029 mole) of copper(l) iodide in 125 mL of acetonitrile was stirred, and a solution of 4.6 mL (0.039 mole) of tert- butyl nitrite in 25 mL of acetonitrile was added dropwise during a 10 minute period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 16 hours. After this time the reaction mixture was poured into 300 mL of water. Excess iodine was destroyed using sodium meta-bisulfite. The mixture was then extracted with two 250 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 1:3 methylene chloride : petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 3.4 grams of 4-fluoro-2-nitro-6-methylphenyl
AP/P/ 9 4/ 0 0 7 9 6 iodide. The NMR spectrum was consistent with the proposed structure. The reaction was repeated to obtain more product.
Step D Synthesis of 4-fluoro-2-nitro-6-methylbenzonitrile as an 5 intermediate
A stirred mixture of 19.0 grams (0.068 mole) of 4-fluoro-2-nitro-6methylphenyl iodide and 7.0 grams (0.078 mole) of copper(l) cyanide in 100 mL of Ν,Ν-dimethylformamide was heated at 150-155 °C for 30
0 minutes. The reaction mixture was then diluted with 400 mL of water and 100 mL of ethyl acetate. The mixture was filtered, and the filtrate was placed in a separatory funnel. The organic layer was separated, and the
C aqueous layer was washed with 200 mL of ethyl acetate. The combined wash and organic layer was then washed with three 150 mL portions of
5 aqueous 5% lithium chloride. The mixture was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 1:1 methylene chloride : petroleum ether. The product-containing fractions were combined and
0 concentrated under reduced pressure, yielding 12.8 grams of 4-fluoro-2nitro-6-methylbenzonitrile, mp 61-63 °C. The NMR spectrum was consistent with the proposed structure.’
Step E Synthesis of 2-amino-4-fluoro-6-methylbenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 1, using 12.5 grams (0.069 mole) of 4-fluoro-2-nitro-6methylbenzonitrile, 25.4 mL (0.251 mole) of cyclohexene, 1.9 grams
0 (catalyst) of 10% palladium on charcoal, and 10 mL of water in 200 mL of ethanol. The yield of 2-amino-4-fluoro-6-methylbenzonitrile was 2.0 grams. The NMR spectrum was consistent with the proposed structure.
Step F Synthesis of 2-amino-5-bromo-4-fluoro-6-methylbenzonitrile 3 5 as an intermediate
AP. Ο Ο 5 Ο 7
ΛΓ
C'· 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 0.5 gram (0.003 mole) of 2-amino-4-fluoro-6methylbenzonitrile and 0.6 gram (0.004 mole) of N-bromosuccinimide in 30 mL of N.N-dimethylformamide. The yield of 2-amino-5-bromo-4-fluoro-6methylbenzonitrile was 0.7 gram. The NMR spectrum was consistent with the proposed structure.
Step G Synthesis of 2-amino-4-fluoro-6-methyl-5-[3,5di(trifluoromethyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 1.3 grams (0.005 mole) of 3,5di(trifluoromethyl)phenylboronic acid, (commerc-ially available) 0.7 gram (0.003 mole) of 2-amino-5-bromo-4-fluoro-6-methylbenzonitrile , 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0), 4.7 mL (0.009 mole) of aqueous 2M sodium carbonate, and 50 mL of toluene. The yield of 2amino-4-fluoro-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]benzonitrile was 0.9 gram. The NMR spectrum was consistent with the proposed structure.
Step H Synthesis of 2,4-diamino-7-fluoro-5-methyl-6-[3,5di(trifluoromethyl)phenyl]-quinazoline (Compound 214)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 0.9 gram (0.002 mole) of 2-amino-4-fluoro-6-methyl5-[3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.3 gram (0.003 mole) of chloroformamidine hydrochloride in 6 mL of diglyme. The yield of 2,4diamino-7-fluoro-5-methyl-6-[3,5-di(trifluoromethyl)-phenyl]quinazoline was 0.4 grams, mp 224-225 °C. The NMR spectrum was consistent with the proposed structure.
AP/P/ 9 4/ 0 0 7 9 6
EXAMPLE 25
SYNTHESIS OF 2,4-DI[(1,1-DIMETHYLETHOXY)CARBONYLAMINO]-5METHYL-6-[3,5-DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 217)
Γ ©
5 r‘ ο 25
A stirred mixture of 2.00 grams (0.0050 mole) of 2,4-diamino-5methyl-6-[3,5-di(trifluoromethyl)phenyl]quinazoline (Compound 63), 0.06 gram (0.0005 mole) of dimethylaminopyridine, and 10.00 grams (0.0458 mole) of di-tert-butyl dicarbonate was heated at 75 °C for about 6 hours. The reaction mixture was cooled and dissolved in ethyl acetate. The solution was passed through a column of silica gel. Elution was accomplished using ethyl acetate. The eluate was concentrated under reduced pressure to a residue. The residue was triturated with hexane to remove unreacted di-tert-butyl dicarbonate. The yield of 2,4-di[(1,1 dimethylethoxy)carbonylamino]-5-methyl-6-[3,5di(trifluoromethyl)phenyl]quinazoline was 1.2 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 26
SYNTHESIS OF 2,4-DIAMINO-5-(1-METHYLETHYL)-6-[3,5DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 219)
Step A Synthesis of 2-methylcarbonylamino-3-(1-methylethyl)nitrobenzene as an intermediate
This compound was prepared in a manner analogous to that of Step A of Example 24, using 19.1 grams (0.141 mole) of 2-(1-methylethyl)aniline and 7.9 mL (0.169 mole) of 90% nitric acid in about 85 mL of acetic anhydride. The yield of 2-methylcarbonylamino-3-(1methylethyl)nitrobenzene was 30.0 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-nitro-6-(1 -methylethyQaniline as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 24, using 30.0 grams (0.135 mole) of 2-methylcarbonylamino-3-(1-methylethyl)nitrobenzene, 50 mL of concentrated hydrochloric acid, and 50 mL of ethanol. The yield of 2-nitro-6-(1-methylethyl)aniline
AP.00507 was 12.8 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-nitro-6-(1-methylethyl)phenyl iodide as an 5 intermediate
This compound was prepared in a manner analogous to that of Step C of Example 24, using 10.7 grams (0.059 mole) 2-nitro-6-(1methylethyl)aniline, 10.5 mL (0.089 mole) of tert.-butyl nitrite, and 15.0
0 grams (0.059 mole) of iodine in 250 mL of acetonitrile. The yield of 2-nitro6-(1-methylethyl)phenyl iodide was 15.2 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-nitro-6-(1-methylethyl)benzonitrile as an 15 intermediate
This compound was prepared in a manner analogous to that of Step D of Example 24, using 15.0 grams (0.052 mole) of 2-nitro-6-(1methylethyl)phenyl iodide and 5.4 mL (0.060 mole) of copper(l) cyanide in
75 mL of N,N-dimethylformamide. The yield of 2-nitro-6-(1methylethyl)benzonitrile was 9.3 grams. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2-amino-6-(1-methylethyl)benzonitrile as an
5 intermediate
This compound was prepared in a manner analogous to that of Step B of Example 1, using 9.3 grams (0.049 mole) of 2-nitro-6-(1methylethyl)benzonitrile 18.0 mL (0.178 mole) of cyclohexene, 2.0 grams
0 (catalyst) of 10% palladium on charcoal, and 10 mL of water in 250 mL of ethanol. The yield of 2-amino-6-(1-methylethyl)benzonitrile was 7.4 grams. The NMR spectrum was consistent with the proposed structure.
Step F
AP/P/ 94/00796
Synthesis of 2-amino-5-bromo-6-(1-methylethyl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 7.0 grams (0.044 mole) of 2-amino-6-(1methylethyl)benzonitrile and 7.8 grams (0.044 mole) of Nbromosuccinimide in 150 mL of Ν,Ν-dimethylformamide. The yield of 25 amino-5-bromo-6-(1-methylethyl)benzonitrile was 8.4 grams, rap 82-85 °C. The NMR spectrum was consistent with the proposed structure.
Step G Synthesis of 2-amino-6-(1-methylethyl)-5-[3,5di(trifluoromethyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 3.1 grams (0.011 mole) of 3,5-di(trifluoromethyl)phenylboronic acid, 1.8 grams (0.008 mole) of 2-amino-5-bromo-6-(1methylethyl)benzonitrile, 0.3 gram (catalyst) of tetrakis(triphenyl1 5 phosphine)palladium(O), 12.0 mL (0.024 mole) of aqueous 2M sodium carbonate, and 200 mL of toluene. The yield of 2-amino-6-(1-methylethyl)5-[3,5-di-(trifluoromethyl)phenyl]benzonitrile was 2.2 grams. The NMR spectrum was consistent with the proposed structure.
Step H Synthesis of 2,4-diamino-5-(1-methylethyl)-6-[3,5di(trifluoromethyl)phenyl]quinazoline (Compound 219)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.9 grams (0.005 mole) of 2-amino-6-(125 methylethyl)-5-[3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.7 gram (0.006 mole) of chloroformamidine hydrochloride in 25 mL of diglyme. The yield of 2,4-diamino-5-(1 -methylethyl)-6-[3,5-di(trifluoromethyl)phenyljquinazoline was 0.4 grams, mp 212-214 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 27
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(2,3-DIHYDRO-2,2DIMETHYL-3-BENZOFURANON-4-YL)QUINAZOLINE (COMPOUND 212)
AP. Ο 0 5 Ο 7
Step A Synthesis of 7-amino-4-bromo-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 10.0 grams (0.061 mole) of 7-amino-2,3-dihydro5 2,2-dimethylbenzofuran in 150 mL of Ν,Ν-dimethylformamide was cooled in an ice-water bath, and a solution of 10.9 grams (0.061 mole) of Nbromosuccinimide in 50 mL of Ν,Ν-dimethylformamide was added in one portion. Upon completion of addition, the reaction mixture was maintained in the ice-water bath for about one hour After this time the reaction mixture
0 was poured into about 600 mL of water. The mixture was then extracted f with two 200 mL portions of diethyl ether. The combined extracts were washed with two 100 mL portions of an aqueous 10% lithium chloride θ solution. The organic layer was dried with magnesium sulfate and filtered.
The filtrate was concentrated under reduced pressure, yielding 12.3 grams 15 of 7-amino-4-bromo-2,3-dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 4-bromo-2,3-dihydro-2,2-dimethylbenzofuran as an intermediate
A stirred solution of 12.3 grams (0.051 mole) of 7-amino-4-bromo2,3-dihydro-2,2-dimethylbenzofuran and 30 mL of toluene in 200 mL of ethanol was cooled in an ice-bath and 5.6 mL (0.102 mole) of concentrated
C sulfuric acid was added slowly, followed by 5.6 grams (0.082 mole) of
5 sodium nitrite. Upon completion of addition, the ice-bath was removed, and the reaction mixture was warmed to 50 °C. The reaction mixture temperature was then brought to about 75 °C, where it was stirred for 30 minutes. After this time the reaction mixture was heated at reflux for one hour and then was poured into 200 mL of water. The mixture was extracted
0 with two 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residual oil. The oil was subjected to column chromatography on silica gel. Elution was accomplished using petroleum ether. The product-containing fractions were combined and concentrated
5 under reduced pressure, yielding 3.6 grams of 4-bromo-2,3-dihydro-2,2AP/P/ 9 4/ 0 0 7 9 6 dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 4-bromo-2,3-dihydro-2,2-dimethyl-35 benzofuranone as an intermediate
Under a nitrogen atmosphere, a stirred solution of 3.0 grams (0.013 mole) 4-bromo-2,3-dihydro-2,2-dimethylbenzofuran, 10.7 grams (0.039 mole).of potassium persulfate, and 3.3 grams (0.013 mole) of copper(ll)
0 sulfate pentahydrate in 30 mL of water and 30 mL of acetonitrile was heated at reflux for one hour. After this time the reaction mixture was poured into 200 mL of water. The mixture was then extracted with one 200 mL portion of diethyl ether. The extract was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a
5 residual oil. The oil was subjected to column chromatography on silica gel.
Elution was accomplished using 1:1 petroleum ether and methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 2.1 grams of 4-bromo-2,3dihydro-2,2-dimethyl-3-benzofuranone. The NMR spectrum was consistent
0 with the proposed structure. Steps A through C were repeated.
Step D Synthesis of 2,4-diamino-5-methylquinazoline (compound 27) as an intermediate
5 This compound was prepared in a manner analogous to that of Step
E of Example 1, using 10.0 grams (0.076 mole) of 2-amino-6methylbenzonitrile (prepared as in Example 1, Step B), and 10.0 grams (0.087 mole) of chloroformamidine hydrochloride in 40 mL of diglyme, yielding 11.5 grams of 2,4-diamino-5-methylquinazoline. The NMR
0 spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-6-acetoxymercurio-5methylquinazoline as an intermediate
5 A solution of 10.0 grams (0.057 mole) of 2,4-diamino-5methylquinazoline and 18.2 grams (0.057 mole) of mercuric acetate in 125
AP. Ο Ο 5 Ο 7 mL of acetic acid is stirred at ambient temperature for about 18 hours. After this time the reaction mixture is poured into 1000 mL of water. The resultant precipitate is collected by filtration and dried, yielding 2,4diamino-6-acetoxymercurio-5-methylquinazoline.
Step F Synthesis of (2,4-diamino-5-methylquinazolin-6-yl)boronic acid as an intermediate
A solution of 17.3 grams (0.040 mole) of 2,4-diamino-61 0 acetoxymercurio-5-methylquinazoline and 38.3 mL (0.400 mole) of boranetetrahydrofuran complex (1.0M in tetrahydrofuran) in 1000 mL of tetrahydrofuran is stirred at ambient temperature for about 30 minutes. The reaction mixture is then poured into water. The resultant precipitate is collected by filtration and dried, yielding (2,4-diamino-5-methylquinazolin1 5 6-yl)boronic acid.
NOTE: The method of S.W. Breuer and F.G. Thorpe (Tetrahedron Lett.No. 42, pp 3719-3720, 1974) is used to prepare 2,4-diamino-52 0 methylquinazolin-6-yl)boronic acid from its 6-acetoxymercurio derivative.
Step G Synthesis of 2,4-diamino-5-methyl-6-(2,3-dihydro-2,2dimethyi-3-benzofuranon-4-yl)quinazoline (compound 212)
5 A solution of 2.1 grams (0.010 mole) of (2,4-diamino-5methylquinazolin-6-yl)boronic acid in 25 mL of Ν,Ν-dimethylformamide is stirred, and 2.1 grams (0.009 mole) of 4-bromo-2,3-dihydro-2,2-dimethyl-3benzofuranone (prepared in Step C of this Example), 2.8 grams (0.020 mole) of potassium carbonate, and 0.31 gram (catalyst-3 mole %) of
0 tetrakis(triphenylphosphine)palladium(0) are added. The reaction mixture is then warmed to 90 °C, where it is stirred for about 16 hours. After this time the reaction mixture is poured into water. The resultant precipitate is collected by filtration and dried, yielding 2,4-diamino-5-methyl-6-(2,3dihydro-2,2-dimethyl-3-benzofuranon-4-yl)quin-azoline.
AP/P/ 9 4 / 0 0 7 9 6
X
NOTE: The methods of A. Suzuki et al. (J. Am. Chem. Soc. 1989, 111, 314 321) and W.C. Shieh et al. (J. Org. Chem. 1992, 57, 379-381) are used to prepare 2,4-0ΐ3Γηΐηο-5-Γηθ!ίιγΙ-6-(2,3<1ϊΙιγ0Γθ-2,2-0ϊΓηβίίιγΙ-35 benzofuranon-4-yl)quinazoline.
AP.00507
Table ..1
Substituted 2.4-Diaminoquinazolines as Insecticides
Where R1, R2, R6 and R7 are hydrogen.
Cmpd, Nq.
H
Cl
F
Br
I
H
H
H
H
H
H
H
H
H
X
H
H
H
H
H
Cl
Cl
NH4+CI complex Br
F
H
H
H
H
H (I)
Ϊ
H
H
H
H
H
H
H
H
H
Cl
Br
F
I
H
H
H
H
H
H
H
H
H
H
H
H
H
H
F
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont'd)
CmDd. No. | W | X | Y | z |
15 | H | Cl | H | Cl |
16 | H | Br | H | Br |
17 | F | F | H | H |
18 | H | F | F | H |
19 | H | H | F | F |
20 | Cl | Br | H | H |
21 | H | Cl | H | Br |
22 | H | Br | H | Cl |
23 | Cl | CN | H | H |
24 | Cl | -NH2 | H | H |
25 | Cl | Br | H | Br |
26 | F | F | F | F |
27 | -CH3 | H | H | H |
28 | H | -CH3 | H | H |
29 | H | H | -CH3 | H |
30 | -CH3 | -NO2 | H | H |
31 | -CH3 | H | H | -NO2 |
32 | -CH3 | -NH2 | H | H |
33 | -cf3 | H | H | H |
34 | H | -cf3 | H | H |
35 | H | H | H | -cf3 |
Table UConid)
AP.00507
Cmpd, No, | X | Ϊ | z | ||
36 | -OC2H5 | H | H | H | |
37 | -OCH2CF3 | H | H | H | |
38 | H | -NH2 | H | H | |
39 | -N(CH3)2 | H | H | H | |
<> | 40 | -CN | H | H | H |
© | 41 | phenyl | H | H | H |
42 | H | phenyl | H | H | |
43 | H | H | phenyl | H | |
44 | H | XU* | H | H | |
45 | H | Xu, | H | H | |
46 | H | (footnote 1) | H | H | |
47 | Cl | phenyl | H | H | |
X‘ ί | 48 | Cl | Xie, | H | H |
49 | Cl | Xlf | H | H | |
50 | Cl | Cl τλ | H | H | |
51 | Cl Methanol Solvate | A | H | H |
AP/r/ 9 4/ 0 0 7 9 6
Table 1 (Cont'd)
Cmpd, No, | W | Ϊ | Z | |
52 | Cl | A | H | H |
53 | Cl | X’ | H | H |
54 | Cl | 90 | H | H |
55 | H | Cl | H | phenyl |
56 | H | phenyl | H | Cl |
57 | phenyl | H | phenyl | H |
58 | H | phenyl monohydrate | H | phenyl |
59 | Cl | phenyl | H | phenyl |
60 | -CH3 | Ά | H | H |
61 | •CH3 Methanol Solvate | CH3 • Ah, | H | H |
62 | -CH3 | Ach, | H | H |
63 | -ch3 | X ^Xf3 | H | H |
64 | ^iCF3 | X x0\5F3 | H | H |
AP. Ο Ο 5 Ο 7
Table 1 (Cont'd)
Where R1, R2, R6, R7, Y and Z are hydrogen; W is chloro; and X is OR3
Ci
Cmpd, No. | |
65 | H |
66 | -CH3 |
67 | -C5H11 |
68 | -C11H23 |
69 | -CH2Si(CH3)3 |
70 | CH,OO |
71 | |
72 | F |
F | |
73 | |
74 | °2Η4Ο>0Ϊ |
6 L 0 0 / <7 6 /d/dV
Table 1 (Cont'd)
Where R1, R2, R6 and R7 are hydrogen.
Cmpd, No, | X | Ϊ | Z | |
75 | H | H | H | |
76 | •s,0,xc: | H | H | H |
77 | SCH'xc | H | H | H |
78 | H | H | H | |
79 | H | H | H | |
80 | H | -st&: | H | H |
81 | H | H | H | |
82 | H | u; | H | H |
83 | H | H | H | |
84 | cis isomer | H | H | H |
85 | πχϊ trans isomer | H | H | H |
86 | SXO | H | H | H |
87 | H | H | H |
Table 1 (Cont'd)
Cmpd, No,
W
H
H
H
AP. Ο Ο 5 Ο 7
-s
-S(O)
Ϊ
H
H
H z
H
H
H
Where R1, R2, R6, R7, Y, and Z are hydrogen; and X is
CmDd. No. | W | QI21 | n | m | B4 |
91 | Cl | -N=CH- | 1 | 0 | H |
92 | Cl | -CH2NH- | 1 Hemimethanol | 0 | H |
93 | -CH3 | -CH2NH- | 1 | 0 | H |
94 | H | -CH2NH- | 1 2-HCI | 1 | H |
95 | H | -CH2NH- | 1 | 1 | -C2H5 |
96 | H | -CH2NH- | 2 2-HCI | 1 | H |
97 | H | -CH2NH- | 2 | 1 | -C2H5 |
98 | H | -CH2NH- | 3 2-HCI | 1 | H |
99 | H | -CH2NH- | 3 | 1 | -C2H5 |
AP/P/ 94/00796
6s
Table 1 (Cont’d)
Cmpd, nq, | w | Ω | n | m | B4 |
100 | Cl | -CH2NH- | 2 | 1 | -C2H5 |
101 | -CH3 | -CH2NH- | 2 2-HCI | 1 | H |
102 | -ch3 | -CH2NH- | 2 | 1 | -C2H5 |
,<··
Where R1, R2, R6 and R7 are hydrogen. Cmod. No W £
103 F H
104 F H
105 H Cl
Y
F
H
H z
H
Cl
F
AP.00507
Table 1 (Cont’d)
Where R1, R2, R®, R7, Y, and Z are hydrogen.
Cmpd. No. | W | X |
106 | H | Cl xi |
107 | H | ch3 aCH> |
108 | H | CHj CHj |
109 | H | CFj 'ύ |
110 | H | OCHj |
111 | H | OCHj Ίφ CFj |
112 | -ch3 | phenyl |
113 | -CH3 | Xrcl |
114 | -CH3 | Xk |
115 | -ch3 |
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No, | W | X |
116 | -ch3 | V Cl |
117 | -ch3 | xx: |
118 | -ch3 | cc, |
119 | -ch3 | |
120 | -ch3 | XXc. |
121 | -ch3 | OCH3 Cl |
122 | -ch3 | XxCHl |
123 | -ch3 | ch3 ch3 |
124 | -ch3 | |
125 | -ch3 | XX‘ |
126 | -ch3 | xx( |
127 | -ch3 | xxc |
Table 1 (Cont'd'
AP.00507
C.mcd,.NQ | w | X |
128 | -CH3 | X^zX^OC2H5 V |
129 | -ch3 | V |
130 | -CH3 | Ό-οο,Η, |
131 | -CH3 | X_^X_,CH2OCH3 v |
132 | -CH3 | XT’ |
133 | -CH3 | ΤΓ |
134 | -CH3 | χΓ |
135 | -CH3 | Χζ^0(Ο)ΝΗ2 |
136 | -ch3 | XiZX^NHC(O)C3H7 V |
137 | -CH3 | XQ^NHS(O)2CH3 |
138 | -CH3 | Xr10 |
139 | -ch3 | -CHjCHj υ |
140 | -CH3 | -ch2ch2_z^_cf3 V |
AP/P/ 9 4 / 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No
141
-CH3
Where R1, R2, R6, R7, Y and Z are hydrogen; W is methyl; and X is
Cmpd. No | Y2 | W2 | 2C | Y2 | zz |
142 | H | H | H | H | H |
143 | H | H | -CF3 | H | H |
144 | H | -cf3 | H | -cf3 | H |
Where R1, R2, R6, R7, Y and Z are hydrogen.
145 | -ch3 | |
146 | -ch3 | |
147 | -ch3 | Λ^-οκ, |
148 | -cf3 | XT |
Table 1 (Cont'd)
AP. Ο Ο 5 Ο 7
Where R1, R2, R6, R7, Y, and Z are hydrogen; W is methyl; and X is:
Cmpd. No. | y: | VL | X | r | ZL |
149 | H | H | H | H | H |
150 | Cl | H | H | H | H |
151 | H | Cl | H | H | H |
152 | H | Cl | H | Cl | H |
153 | H | Cl | Cl | H | H |
154 | H | H | ci | H | H |
155 | -cf3 | H | H | H | H |
156 | H | -cf3 | H | H | H |
157 | H | -cf3 | H | -cf3 | H |
158 | H | H | -cf3 | H | H |
159 | H | -CO2CH3 | H | H | H |
160 | F | H | H | H | H |
161 | H | H | -CO2CH3 | H | H |
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No, | XL | w: | x: | r | £ |
162 | H | F | H | H | H |
163 | H | -CN | H | H | H |
164 | H | F | H | F | H |
165 | H | H | -CN | H | H |
166 | H | H | F | H | H |
167 | F | H | F | H | F |
168 | H | XX | H | H | H |
169 | H | XX | H | H | H |
170 | H | XX, | H | H | H |
171 | H | H | XX | H | H |
172 | H | H | XX, | H | H |
173 | H | H | XX, | H | H |
Table 1 (Cont’d)
AP . Ο Ο 5 Ο 7
Where R1, R2,R6, R7, Y, and Z are hydrogen
Cmpd, No, | W | y: | YE | £ | r | z: |
174 | H | H | H | Cl | Cl | H |
175 | Cl | H | H | Cl | Cl | H |
Where R1, R2, r6, r7, γ and Z are hydrogen: and W is methyl
CmDd. No. | |
176 | V COOH |
177 | v0Fs COjCH3 |
178 | v F |
179 | XT ethanesulfonic acid salt |
180 | ΧΓΗ’ |
181 | V |
AP/P/ 9 4 / 0 0 7 9 6
Table 1 (Cont'd)
Where R1, R2, R6, R7, Y and Z are hydrogen; W is methyl; and X is
Cmod, No V2
182 H
W2
-CF3
Ϊ2
H
Where R1, R2, R6, R7, Y and Z are hydrogen, and W is methyl
Cmpd. No,
183
X
ethanesulfonic acid salt
184
185
SOjC^
186
AP.00507
Table 1 (Cont'd)
Cmpd, No,
187
188 o
189
190
191 och3 a
AP/P/ 94/00796
ci
Table 1 (Cont’d)
AP . 0 0 5 0 7
Table 1 (Cont'd)
Cmpd, No,
197
198
199
X
200
AP/P/ 94/00796
201
Table 1 (Cont'd)
208 o
-CH, 'CHa
AP . Ο Ο 5 Ο 7
IablS-UCpnTd)
Cmpd, No,
209
210
211
212
o
AP/P/ 9 4 / 0 0 7 9 6
Where R1, R2, R®, R7, and Z are hydrogen, W is methyl, and Y is fluoro
Cmpd, No.
213
214
Table 1 (Cont'd)
Where R1, R6, Y and Z are hydrogen, and W is methyl
CmpdJlL R2 q7
215
216
C(CHj)3
CiCH;j)3
217
I A ' OC(CH3)3 '
OC(CH3)3
Where R1, R2, R6, R7, Y and Z are hydrogen, and W is 1-methylethyl [i.e., -CH(CH3)2]
AP .0 0 5 0 7
Table 1 (Cont'd)
Where R1, R2 *, R6, R7, Y and Z are hydrogen r
i
Cmpd, No, W
220 H
221 F
222 F
X
FOOTNOTES 1)ln Compound 46, X is
-CH2N(CH3)
O COOH o
II I II
C-NH-CHCH2CH2-C-OH 2hn Compounds 91-102, the left hand portion of the moiety Q, is attached to the quinazoline ring.
AP/P/ 9 4 / 0 0 7 9 6
Table 1-.3
Melting Points and Empirical Formulas of Compounds of Table 1
COMPOUND | MELTING POINT (°C) | EMPIRICAL FORMULA |
1 | 240-246 | C8H8N4 |
2 | 186-188 | C8H7CIN4 |
3 | 249-251 | C8H7FN4 |
4 | 202-204 | C8H7BrN4 |
5 | 192-193 | C8H7IN4 |
6 | 264-270 | C8H7CIN4 |
7 | >360 | C8H11CI2N5 |
8 | 264-266 | C8H7BrN4 |
9 | 315-320 | C8H7FN4 |
10 | 246-247 | C8H7CIN4 |
11 | 255-256 | CeH7BrN4 |
12 | 274-277 | C8H7FN4 |
13 | 266-267 | C8H7IN4 |
14 | 285-287 | C8H7FN4 |
15 | >320 | C8H6CI2N4 |
16 | >256 | CeH6Br2N4 |
17 | 256-257 | C8H6F2N4 |
18 | 172-173 | C8H6F2N4 |
19 | 295-296 | C8H6F2N4 |
20 | 273-275 | C8H6B1CIN4 |
21 | >325 | C8H6BrCIN4 |
22 | >325 | CeH6BrCIN4 |
23 | 287, dec. | C9H6CIN5 |
24 | 204-205 | C8H8CIN5 |
25 | 188-198 | CeH5Br2CIN4 |
26 | 215-220 | C8H4F4N4 |
27 | 210-212 | C9H10N4 |
28 | 250-253 | C9H10N4 |
29 | 226-227 | C9H10N4 |
30 | 228, dec. | C9H9N5O2 |
31 | 293, dec. | C9H9N5O2 |
32 | 219-222 | C9H11N5 |
33 | 176-178 | C9H7F3N4 |
34 | 234-236 | C9H7F3N4 |
35 | 244-246 | C9H7F3N4 |
36 | 214-216 | C10H12N4O |
37 | 245-246 | C10H9F3N4O |
38 | 255-258 | C8H9N5 |
40 | 231-232 | C9H7N5 |
41 | 249-259 | C14H12N4 |
EMPIRICAL FORMULA
COMPOUND
MELTING POINT (°C)
42 | 244 partial, 255-257 | C14H12N4 |
43 | 254-258 | C14H-12N4 |
44 | 287-290 | C18H20N4 |
45 | 256-259 | CI6H10F6N4 |
46 | 208-210, dec. | C22H24N6O5 |
47 | 248-251 | C14H11CIN4 |
48 | 256-259 | C14H10CI2N4 |
49 | 268-280 | C14H10CIFN4 |
50 | 238-240 | C14H9CI3N4 |
51 | 245-250 | C15H13CI3N4O |
52 | 222-225 | C14H9CI2FN4 |
53 | >280 | C16H9CIF6N4 |
54 | 224-229 | C18H13CIN4 |
55 | 264-268 | C14H11CIN4 |
56 | 230-238, dec. | C14H11CIN4 |
57 | 115-125 | C20H16N4 |
58 | 250-258, dec. | C20H18N4O |
59 | 238-242. dec. | C20H15CIN4 |
60 | 245-247 | C16H16N4 |
61 | 251-253 | C18H22N4O |
62 | 308-311, dec. | C19H22N4 |
63 | 222-225 | C17H12F6N4 |
64 | 187-191 | C24H12F12N4 |
65 | C14H10CI2N4O | |
66 | — | C15H12CI2N4O |
67 | 157-162 | C19H20CI2N4O |
68 | C25H32CI2N4O | |
69 | 180-183 | C18H29CI2N4O |
70 | C21H15CI3N4OS1 | |
71 | — | C24H21CI3N4O |
72 | 97-110 | C21H11CI2F5N4O |
73 | 112-120 | C20H15CI2N5O |
74 | 105-112 | C25H24CI2N4O4S |
75 | 232-234 | C14H10CIN4O |
76 | 268-270 | C14H10CI2N4O2S |
77 | 197-199 | C15H12N4S |
78 | 200-205 | C15H12N4S |
79 | 178-180 | CI6HI6N4 |
80 | 232-234 | C14H10CI2N4S |
81 | >250 | C14H10CI2N4OS |
82 | 286-289 | C14H10CI2N4O2S |
83 | 227-229.5 | C20HI8N4 |
84 | 223-224 | C20H16N4 |
85 | 257-258, dec. | C20HI6N4 |
AP/P/ 9 4 / 0 0 7 9 6
COMPOUND MELTING POINT (°C) EMPIRICAL FORMULA
86 | 218-219.5 | C18H14N4S |
87 | 217-219 | C18H14N4OS |
88 | 235-237 | C18H14N4S |
89 | 312-314 | C18H14N4OS |
90 | 300-302 | C18H14N4O2S |
91 | 234-235 | C18H18CIN5O3 |
92 | 115-117 | C19H24CIN5O4 |
93 | 95-210 | C21H29N5O6 |
94 | 195, dec. | C19H23CI2N5O5 |
95 | 147-148.5 | C21H25N5O5 |
96 | 204 | C20H25CIN5O5 |
97 | 70-72 | C22H27N5O5 |
98 | 205, dec. | C21H27CI2N5O5 |
99 | 120-125 | C23H29N5O5 |
100 | 190-191 | C22H26CIN5O5 |
101 | 210, dec. | C21H27CI2N5O5 |
102 | 169-171 | C23H29N5O5 |
103 | 223-225 | C8H6F2N4 |
104 | 265-267 | C8H6CIFN4 |
105 | 295, dec. | C8H6CIFN4 |
106 | 240-245 | C14H11CIN4 |
107 | 277-278 | C16H16N4 |
108 | 282-285 | C18H20N4 |
109 | 235-237 | C15H11F3N4 |
110 | 207 | C15H14N4O |
111 | 203-206 | C16H13F3N4O |
112 | >250 | C15H14N4 |
113 | 225-229 | C15H13CIN4 |
114 | >250 | C15H13CIN4 |
115 | >250 | C15H13FN4 |
116 | >250 | C15H12CI2N4 |
117 | >250 | C15H12CIFN4 |
118 | >250 | C16H16N4 |
119 | >250 | C16H16N4 |
120 | >250 | C17H18N4 |
121 | 239-241 | C16HI5CIN4O |
122 | >250 | C17H18N4 |
123 | >250 | C18H20N4 |
124 | 208-210 | C16H13F3N4 |
125 | 224-226 | C16H13F3N4 |
126 | 232-235 | C16H13F3N4 |
127 | 185-190 | C19H13F9N4 |
128 | >250 | C17HI8N4O |
129 | >250 | C18H20N4O |
AP . 0 0 5 0 7
COMPOUND | MELTING POINT (°C1 | EMPIRICAL FORMULA |
130 | >250 | C18H20N4O |
131 | 238-244 | C17H18N4O |
132 | >250 | CI6H13F3N4O |
133 | 265-270 | C16H13N5 |
134 | >250 | C15H13N5O2 |
135 | 279-283 | C16H15N5O |
136 | >250 | C19H21N5O |
137 | 274-275 | C16H17N5O2S |
138 | 263-268 | C21H18N4 |
139 | 197-201 | C17H18N4 |
140 | 209-212 | C18H17F3N4 |
141 | 122-123 | C19H16F6N4 |
142 | >300 | C17H15CIN4 |
143 | >300 | C18H14CIF3N4 |
144 | >350 | C19H13CIF6N4 |
145 | 293-295 | C13H12N4S |
146 | 270-272 | C13H11CIN4S |
147 | 258-260 | C14H14N4S |
148 | 202-204 | C16H10F6N4 |
149 | — | C15H12N4O |
150 | C15H11CIN4O | |
151 | C15HI1CIN4O | |
152 | — | C15H10CI2N4O |
153 | C15H10CI2N4O | |
154 | C15H11CIN4O | |
155 | C16H11.F3N4O | |
156 | C16H11F3N4O | |
157 | C17H10F6N4O | |
158 | C16H11F3N4O | |
159 | — | C17H14N4O3 |
160 | C15H11FN4O | |
161 | C17H14N4O3 | |
162 | — | C15H11FN4O |
163 | C15H11FN4O | |
164 | C15H10F2N4O | |
165 | — | C15H11FN4O |
166 | C15H11FN4O | |
167 | C15H9F3N4O | |
168 | C21H15FN4O | |
169 | C21H15CIN4O | |
170 | C22H15F3N4O | |
171 | C21H15FN4O | |
172 | C21H15CIN4O | |
173 | C22H15F3N4O |
6 L 0 0 / V 6 ,'d/dV
Θ4
COMPOUND MELTING POINT (°C) EMPIRICAL FORMULA
174 | 238-240, dec. | C16H13CI2N5O |
175 | 248-250, dec. | CI6H12CI3N5O |
176 | — | C17H13F3N4O2 |
177 | C18H15F3N4O2 | |
178 | CI5H12F2N4 | |
179 | 315-320, dec. | C18H19F3N4O3S |
180 | 257-262 | C16H16N4S |
181 | 248 | C17H18N4S |
182 | 325-330 | C18H14CIF3N4 |
183 | 314-320, Dec. | C17H19CIN4O3S |
184 | 279 | C17H18N4O2S |
185 | 188-192 | C19H22N4S |
186 | 235-237 | C19H22N4O2S |
187 | 252-254 | C16H15CIN4O |
188 | 225-226 | C16H12F4N4 |
189 | >350 | C17H13F3N4O |
190 | 245-248 | C21H18N4 |
191 | — | C21H17CIN4 |
192 | >250 | C21H16F2N4 |
193 | >250 | C21H16F2N4 |
194 | — | C22H17F3N4 |
195 | >230 | C21H17CIN4 |
196 | — | C21H17FN4 |
197 | 195-199 | C22H17F3N4 |
198 | 197-200 | C21H16CIFN4 |
199 | 198-200 | C21H16F2N4 |
200 | C22H20N4 | |
201 | 260 | C22H19CIN4 |
202 | 257 | C22H19FN4 |
203 | — | C22H19F3N4 |
204 | 217 | C21H18N4O |
205 | 202 | C21H17CIN4O |
206 | 209 | C21H17FN4O |
207 | 217-218 | C21H16F2N4O |
208 | 240-244 | C19H20N4O |
209 | 207-210 | C19H20N4O |
210 | 257-263 | C19H19CIN4O |
211 | 259-262 | C19H19CIN4O |
212 | C19H18N4O2 | |
213 | 242-246 | C15H11F3N4 |
214 | 224-225 | C17H11F7N4 |
215 | Oil | C21H16F6N4O2 |
216 | 225-226 | C27H28F6N4O2 |
217 | >250 | C27H28F6N4O4 |
AP. Ο Ο 5 Ο 7
COMPOUND | MELTING POINT (°C) | EMPIRICAL-FORMULA |
218 | 251-252 | C17H16F2N4 |
219 | 212-214 | C19H16F6N4 |
220 | C23H23N5OS | |
221 | C16H14FN5O2 | |
222 | — | C17H16FN5O2 |
(Ο σ>
Ο ο
<□>
£Χ
CL <
κ.
»
Insecticide Formulations
In the normal use of the insecticidal quinazolines of the present invention, they usually will not be employed free from admixture or dilution, but ordinarily will be used in a suitable formulated composition compatible with the method of application and comprising an insecticidally effective amount of the quinazoline. The quinazolines of this invention, like most pesticidal agents, may be blended with the agriculturally acceptable surface-active agents and carriers normally employed for facilitating the dispersion of active ingredients, recognizing the accepted fact that the
0 formulation and mode of application of an insecticide may affect the activity of the material. The present quinazolines may be applied, for example, as sprays, dusts, or granules to the area where pest control is desired, the type of application varying of course with the pest and the environment. Thus, the quinazolines of this invention may be formulated as granules of
5 large particle size, as powdery dusts, as wettable powders, as emulsifiable concentrates, as solutions, and the like. It will be understood that the insecticides themselves may be present as essentially pure compounds, or as mixtures of these quinazoline compounds.
Granules may comprise porous or nonporous particles, such as
0 attapulgite clay or sand, for example, which serve as carriers for the _ quinazolines. The granule particles are relatively large, a diameter of ’· about 400-2500 microns typically. The particles are either impregnated with the quinazoline from solution or coated with the quinazoline, adhesive sometimes being employed. Granules generally contain 0.05-10%,
5 preferably 0.5-5%, active ingredient as the insecticidally effective amount.
Dusts are admixtures of the quinazolines with finely divided solids such as talc, attapulgite clay, kieselguhr, pyrophyllite, chalk, diatomaceous earths, calcium phosphates, calcium and magnesium carbonates, sulfur, flours, and other organic and inorganic solids which acts carriers for the
0 insecticide. These finely divided solids have an average particle size of less than about 50 microns. A typical dust formulation useful for controlling insects contains 1 part of 2,4-diamino-5-methyl-6-[3,5-di(trifluoromethyl)phenyl]quinazoline (Compound 63) and 99 parts of talc.
The quinazolines of the present invention may be made into liquid 3 5 concentrates by dissolution or emulsification in suitable liquids and into solid concentrates by admixture with talc, clays, and other known solid
AP .0 0 5 0 7 carriers used in the pesticide art. The concentrates are compositions containing, as an insecticidally effective amount, about 5-50% quinazoline, and 95-50% inert material, which includes surface-active dispersing, emulsifying, and wetting agents, but even higher concentrations of active ingredient may be employed experimentally. The concentrates are diluted with water or other liquids for practical application as sprays, or with additional solid carrier for use as dusts.
By way of illustration, compound 63 was formulated as a 10% wettable 10 powder (10% WP) as follows:
COMPONENT AMOUNT (Wt/Wt)
Compound 63 10.1%
Wetting Agent 5.0%
Dispersing Agent 3.8%
Wetting/Dispersing Agent 0.9%
Diluent 80.2%
Manufacturing concentrates are useful for shipping low melting products of this invention. Such concentrates are prepared by melting the
5 low melting solid products together with one percent or more of a solvent to produce a concentrate which does not solidify on cooling to the freezing point of the pure product or below.
Useful liquid concentrates include the emulsifiable concentrates, which are homogeneous liquid or paste compositions readily dispersed in
0 water or other liquid earners. They may consist entirely of the quinazolines with a liquid or solid emulsifying agent, or they may also contain a liquid carrier such as xylene, heavy aromatic naphthas, isophorone and other relatively non-volatile organic solvents. For application, these concentrates are dispersed in water or other liquid carriers and normally applied as
5 sprays to areas to be treated.
Typical surface-active wetting, dispersing, and emulsifying agents used in pesticidal formulations include, for example, the alkyl and alkylaryl sulfonates and sulfates and their sodium salts, including fatty methyl taurides; alkylaryl polyether alcohols; sulfates of higher alcohols; polyvinyl
0 alcohols; polyethylene oxides; sulfonated animal and vegetable oils;
sulfonated petroleum oils; fatty acid esters of polyhydric alcohols and the
AP/P/ 9 4/ 0 0 7 9 6 ethylene oxide addition products of such esters: and the addition products of long-chain mercaptans and ethylene oxide. Many other types of useful surface-active agents are available in commerce. The surface-active agent, when used, normally comprises about 1-15% by weight of the insecticidal composition.
Other useful formulations include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentrations, such as acetone or other organic solvents.
As shown in the biological test methods below, the compounds of the present invention were tested in the laboratory as dimethylsulfoxide solutions incorporated into an artificial insect diet or as aqueous acetone or methanol solutions containing a small amount of octylphenoxypolyethoxyethanol surfactant for use as foliar sprays. An insecticidally effective amount of quinazoline in an insecticidal composition diluted for application is normally in the range of about 0.001% to about 8% by weight. Many variations of spraying and dusting compositions known in the art may be used by substituting the quinazoline of this invention into compositions known or apparent in the art.
The insecticidal compositions of this invention may be formulated with other active ingredients, including other insecticides, nematicides, acaricides, fungicides, plant growth regulators, fertilizers, etc.
In using the compositions to control insects, it is only necessary that an insecticidally effective amount of quinazoline be applied to the locus where control is desired. Such locus may, e.g., be the insects themselves, plants upon which the insects feed, or the insect habitat. When the locus is the soil, e.g., soil in which agricultural crops are or will be planted, the active compound may be applied to and optionally incorporated into the soil. For most applications, an insecticidally effective amount will be about 75 to 4000 g per hectare, preferably 150 g to 3000 g per hectare.
Biological Data
The substituted 2,4-diaminoquinazolines of the present invention were incorporated into an artificial diet for evaluation of insecticidal activity against the tobacco budworm (Heliothis virescens [Fabricius]).
Stock solutions of test chemical in dimethylsulfoxide were prepared for each rate of application. The rates of application, expressed as the
AP . 0 0 5 0 7 negative log of the molar concentration, and the corresponding concentrations of the stock solution prepared for each rate are shown below:
Stock Solution
Rate of Application micromolar 4
5
0.5 6
0.05 7
0.005 8
One hundred microliters of each of the stock solutions was manually stirred into 50 mL of a molten (65-70 °C) wheat germ-based artificial diet. The 50 mL of molten diet containing the test chemical was poured evenly into twenty wells in the outer four rows of a twenty-five well, five row plastic tray. Each well in the tray was about 1 cm in depth, with an opening of 3 cm by 4 cm at the lip. Molten diet containing only dimethylsulfoxide at the levels used in the test chemical-treated diet was poured into the five wells in the
0 third row of the tray. Each tray therefore contained one test chemical at a single rate of application, together with an untreated control.
Single second instar tobacco budworm larvae were placed in each well. The larvae were selected at a stage of growth at which they uniformly weigh about 5 mg each. Upon completion of infestation, a sheet of clear
5 plastic was heat-sealed over the top of the tray using a common household flat iron. The trays were held at 25 °C at 60% relative humidity for five days in a growth chamber. Lighting was set at 14 hours of light and 10 hours of darkness.
After the 5-day exposure period, mortality counts were taken, and
0 the surviving insects were weighed. From the weights of the surviving insects that fed on the treated diet as compared to those insects that fed on the untreated diet, the percent growth inhibition caused by each test chemical was determined. From these data, the negative log of the concentration of the test chemical that provided 50% growth inhibition
5 (PI50) was determined by linear regression, when possible, for each test chemical. Where possible, the negative log of the concentration of the test chemical that provided 50% mortality (PLC50) was also determined.
6 L 0 0 / *r 6 /d/dV (
C 25
Generally, the compounds of the present invention inhibited the growth of tobacco budworm. Amongst the most efficacious compounds were Compounds 51 -53, 61, 63, 66, 113, 115-117, 125, 128, 129, 143, and 178-182 with pl50 values of greater than 6.3. Compounds 53, 63, and 129, were highly active compounds with pl50 values of greater than 6.7. All of the compounds exemplified above caused some insect mortality in this test. These data are presented in Table 2.
Certain substituted-2,4-diaminoquinazoline derivatives with high plgO values from the diet test were tested for insecticidal activity in foliar evaluations against the tobacco budworm, beet armyworm (Spodoptera exigua Hubnerj), and the cabbage looper (Trichoptusia ni [Hubnerj).
In these tests against the tobacco budworm and the beet armyworm, nine-day-old chick pea plants (Cicer arietinum) were sprayed at 20 psi to runoff on both upper and lower leaf surfaces with solutions of test chemical to provide application rates as high as 1000 ppm of test chemical. The solvent used to prepare the solutions of test chemical was 10% acetone or methanol (v/v) and 0.1% of the surfactant octylphenoxypolyethoxyethanol in distilled water. Four replicates, each containing four chick pea plants, for each rate of application of test chemical were sprayed. The treated plants were transferred to a hood where they were kept until the spray had dried.
The four chick pea plants in each replicate treated with test chemical as described above were removed from their pots by cutting the stems just above the soil line. The excised leaves and stems from the four plants in each replicate were placed in individual 8-ounce paper cups, which contained a moistened filter paper. Five second-instar (4-5 days old) tobacco budworms or beet armywomns were counted into each cup, taking care not to cause injury. An opaque plastic lid was placed on each cup, which was then held in a growth chamber for a 96 hour exposure period at 25°C and 50% relative humidity. At the end of the 96 hour exposure period the cups were opened, and the numbers of dead and live insects were counted. Moribund larvae which were disoriented or unable to crawl normally were counted as dead. Using the insect counts, the efficacy of the test chemical was expressed in percent mortality. The condition of the test plants was also observed for phytotoxicity and for reduction of feeding damage as compared to an untreated control. Where applicable,
AP·00507
1 computer-generated LC50 values were determined from the percentages of insect mortality.
Foliar tests with cabbage looper were conducted in the same manner as described above, the difference being that pinto bean plants (Phaseolus vulgaris) were used.
Of the compounds evaluated on foliage for insecticidal activity, the more active ones included Compounds 63, 116, and 143 of Table 1. Of these, Compound 143 was one of the most effective, providing excellent mortality of all three insect species in the foliar tests.
0 It will also be noted that certain of the 2,4-diaminoquinazolines are very active in the Diet Test against tobacco budworm, and in the Foliar Test against tobacco budworm, cabbage looper, and beet armyworm. Thus, compounds 185, 186, 188, 190-196, 198, 199, 202, 204-211, 213-215,
217,. 218, and 219 all have plso values of 6.1 or higher in the Diet Test.
σ>
r**
-4“
Ο.
w-Q.
Iabls_2
Insecticidal Activity of Substituted-2,4-diaminoquinazolines Incorporated into the Diet of Tobacco Budworm
Cmpd. No. | Rate of ADDlication1 | Percent Growth Inhibition2·3·4 | Cl505 | Percent Mortality6 | pLCso7 |
2 | 8 | ND | <4.0 | 0 | .—. |
7 | ND | 0 | |||
6 | -20 | 0 | |||
5 | -11 | 0 | |||
4 | 33 | 20 | |||
3 | 4 | 7 | .... | 0 | —- |
4 | 5 | 13 | .... | 0 | |
5 | 5 | -14 | <4.0 | 0 | |
8 | 4 | 21 | <4.0 | 0 | |
9 | 4 | 5 | 0 | ||
10 | 4 | 1 | .... | 0 | |
11 | 4 | -3 | .... | 0 | |
12 | 4 | -12 | 0 | . ·— | |
13 | 4 | -4 | 0 | — | |
14 | 4 | -18 | 0 | ||
16 | 4 | 5 | 0 | ||
17 | 4 | -15 | 0 | ||
19 | 4 | -8 | —- | 0 | |
20 | 7 | ND | 4.5 | 0 | .... |
6 | 9 | 0 | |||
5 | 15 | 0 | |||
4 | 84 | 15 | |||
21 | 4 | 23 | <4.0 | 0 | |
22 | 4 | -2 | .... | 0 |
AP. Ο Ο 5 Ο 7
Table 2 (Cont'd'
Rate of | Percent Growth | Percent | ||
Cmod. No. | Aoplication1 | Inhibition2·3·4 | Cl505 | Mortality6 uL£so7 |
25 | 7 | ND | .... | 0 ---- |
6 | ND | 0 | ||
5 | 7 | 0 | ||
4 | 12 | 0 | ||
26 | 4 | 17 | o | |
27 | 5 | 14 | .... | o |
4 | 20 | 0 | ||
28 | 4 | 12 | o | |
29 | 4 | -7 | o | |
30 | 4 | 42 | <4.0 | o |
31 | 4 | 8 | o | |
33 | 4 | 13 | o | |
34 | 4 | 31 | <4.0 | o |
36 | 4 | 7 | o | |
37 | 4 | 23 | <4.0 | o |
38 | 4 | -4 | o | |
39 | 4 | TRACE | o | |
40 | 4 | 9 | o | |
41 | 4 | 4 | o | |
42 | 6 | -4 | .... | o |
5 | 10 | 0 | ||
4 | 17 | 0 | ||
45 | 6 | -2 | 4.9 | o |
5 | 56 | 0 | ||
4 | 82 | 0 |
AP/P/ 9 4 / 0 0 7 9 6
Table 2 (Cont’d)
Cmpd. No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Cl505 | Percent Mortality6 |
46 | 5 | 4 | 4.4 | 0 |
4 | 82 | 0 | ||
47 | 7 | 20 | 5.0 | 0 |
6 | 15 | 0 | ||
5 | 54 | 0 | ||
4 | 84 | 0 | ||
48 | 8 | 20 | 6.3 | 0 |
7 | 26 | 0 | ||
6 | 63 | 10 | ||
5 | 93 | 50 | ||
4 | 100 | 85 | ||
49 | 7 | -6 | 6.1 | 0 |
6 | 63 | 5 | ||
5 | 98 | 45 | ||
4 | 97 | 60 | ||
50 | 7 | -5 | 5.3 | 0 |
6 | 23 | 0 | ||
5 | 68 | 10 | ||
4 | 93 | 40 | ||
8 | 1 | 5.8 | 0 | |
7 | 0 | 0 | ||
6 | 47 | 0 | ||
5 | 83 | 20 | ||
4 | 92 | 30 | ||
51 | 7 | 7 | 6.5 | 0 |
6 | 88 | 20 | ||
5 | 99 | 90 | ||
4 | 100 | 95 | ||
8 | 5 | 6.8 | 0 | |
7 | 25 | 0 | ||
6 | 87 | 35 | ||
5 | 97 | 65 | ||
4 | 99 | 85 |
fiLC507
4.5 <4.0 <4.0
5.6
5.4
AP . Ο Ο 5 Ο 7
Table 2-iCflnttU
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | also5 | Percent Mortality6 | aLCso7 |
52 | 7 | -8 | 6.4 | 0 | <4.0 |
6 | 93 | 10 | |||
5 | 95 | 25 | |||
4 | 97 | 45 | |||
7 | 32 | 6.7 | 0 | 5.8 | |
6 | 93 | 30 | |||
5 | 100 | 95 | |||
4 | 100 | 95 | |||
53 | 7 | 46 | 6.9 | 10 | 5.6 |
6 | 90 | 25 | |||
5 | 100 | 95 | |||
4 | 100 | 95 | |||
54 | 7 | 9 | 6.1 | 0 | <4.0 |
6 | 64 | 5 | |||
5 | 94 | 25 | |||
4 | 96 | 35 | |||
55 | 4 | 21 | <4.0 | 0 | |
56 | 4 | 6 | — | 0 | — |
58 | 4 | 16 | 0 | — | |
59 | 4 | 24 | <4.0 | 0 | — |
60 | 7 | 7 | 6.1 | 0 | 4.6 |
6 | 63 | 5 | |||
5 | 95 | 25 | |||
4 | 99 | 75 | |||
61 | 8 | 9 | 6.7 | 0 | <4.0 |
7 | 49 | 0 | |||
6 | 78 | 5 | |||
5 | 92 | 10 | |||
4 | 96 | 35 |
AP/P/ 9 4 / 0 0 7 9 6
Table 2 (Cont’d)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2’3,4 | Cl505 | Percent Mortality6 | CL£507 |
61 | 8 | -6 | 6.5 | 0 | 4.0 |
(cont.) | 7 | 36 | 0 | ||
6 | 79 | 15 | |||
5 | 96 | 20 | |||
4 | 99 | 50 | |||
62 | 5 | 32 | 4.2 | 0 | |
4 | 54 | 0 | |||
63 | 7 | 5 | 5.9 | 0 | |
6 | 41 | 0 | |||
5 | 86 | 0 | |||
4 | 96 | 15 | |||
7 | 81 | >7.0 | 55 | >7.0 | |
6 | 94 | 60 | |||
5 | 100 | 95 | |||
4 | 100 | 95 | |||
64 | 6 | -2 | 4.8 | 0 | |
5 | 34 | 0 | |||
4 | 93 | 0 | |||
65 | 5 | 6 | 0 | — | |
4 | 3 | 5 | |||
66 | 7 | 36 | 6.7 | 0 | — |
6 | 82 | 0 | |||
5 | 92 | 0 | |||
4 | 97 | 20 | |||
8 | 2 | 6.5 | 0 | <4.0 | |
7 | 19 | 0 | |||
6 | 84 | 0 | |||
5 | 94 | 0 | |||
4 | 98 | 35 | |||
8 | 7 | 6.7 | 0 | <4.0 | |
7 | 24 | 0 | |||
6 | 83 | 0 | |||
5 | 94 | 5 | |||
4 | 99 | 45 |
Tab.le-2IC.QDtd)
AP.00507
Cmpd. Bq. | Rate of Application1 | Percent Growth Inhibition2·3·4 | plso5 | Percent Mortality6 | pLCso7 |
67 | 6 | 16 | 5.0 | 0 | .... |
5 | 46 | 0 | |||
4 | 86 | 10 | |||
68 | 6 | 0 | 5.0 | 0 | <4.0 |
5 | 53 | 0 | |||
4 | 94 | 35 | |||
6 | 3 | 4.9 | 0 | <4.0 | |
5 | 44 | 0 | |||
4 | 94 | 25 | |||
69 | 6 | 34 | 5.2 | 0 | |
5 | 50 | 0 | |||
4 | 86 | 5 | |||
70 | 6 | 15 | 5.5 | 0 | 4.3 |
5 | 85 | 0 | |||
4 | 99 | 75 | |||
71 | 6 | -8 | 4.7 | 0 | —« |
5 | 48 | 0 | |||
4 | 70 | 0 | |||
6 | 5 | 4.3 | 0 | — | |
5 | 9 | 0 | |||
4 | 65 | 0 | |||
72 | 6 | 1 | 5.1 | 0 | — |
5 | 72 | 0 | |||
4 | 95 | 25 | |||
73 | 6 | 58 | 0 | — | |
5 | 89 | 5 | |||
4 | 95 | 10 | |||
7 | 7 | 6.1 | 0 | — | |
6 | 71 | 0 | |||
5 | 91 | 0 |
AP/P/ 9 4 / 0 0 7 9 6 f '
Table 2 (Confd)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Cl505 | Percent Mortality6 |
73 (cont) | 4 | 94 | 15 | |
74 | 7 | 3 | 5.0 | 0 |
6 | 6 | 0 | ||
5 | 59 | 0 | ||
4 | 87 | 5 | ||
75 | 5 | 14 | <4.0 | 0 |
4 | 34 | 0 | ||
76 | 4 | 16 | —- | 0 |
77 | 6 | 3 | 4.4 | 0 |
5 | 13 | 0 | ||
4 | 75 | 30 | ||
78 | 6 | 27 | 4.6 | 0 |
5 | 33 | 0 | ||
4 | 63 | 0 | ||
79 | 5 | 14 | 4.1 | 0 |
4 | 56 | 0 | ||
80 | 5 | 30 | 4.7 | 0 |
4 | 89 | 20 | ||
81 | 6 | -7 | 4.7 | 0 |
5 | 28 | 0 | ||
4 | 91 | 20 | ||
82 | 8 | 23 | 5.8 | 5 |
7 | 15 | 0 | ||
6 | 28 | 0 | ||
5 | 84 | 40 | ||
4 | 97 | 95 | ||
7 | 12 | 5.5 | 0 | |
6 | 11 | 0 | ||
5 | 87 | 5 |
CLQ507 <4.0
4.9
4.0
AP . Ο Ο 5 Ο 7
Table 2 (Cont'd)
CffiPCLfcifi· | Rate of Application1 | Percent Growth Inhibition2’3·4 | Pl505 | Percent Mortality6 oLCso7 |
82 (cont.) | 4 | 97 | 50 | |
83 | 6 | 9 | 4.7 | o |
5 | 25 | 0 | ||
4 | 77 | 5 | ||
84 | 6 | 19 | 4.3 | 0 |
5 | 20 | 0 | ||
4 | 56 | 5 | ||
85 | 4 | -6 | 0 | |
86 | 6 | 16 | <4.0 | 0 |
5 | 15 | 0 | ||
4 | 30 | 0 | ||
87 | 4 | -6 | 0 | |
88 | 6 | -28 | 4.8 | 0 |
5 | 47 | 0 | ||
4 | 88 | 15 | ||
6 | 15 | 5.0 | 0 | |
5 | 46 | & | ||
4 | 85 | 10 | ||
89 | 6 | 19 | 5.0 | 0 |
5 | 49 | 0 | ||
4 | 87 | 0 | ||
90 | 7 | 23 | 5.3 | o |
6 | 26 | 0 | ||
5 | 69 | 0 | ||
4 | 84 | 10 | ||
91 | 6 | 39 | 4.7 | o |
5 | 36 | 0 | ||
4 | 88 | 10 | ||
92 | 7 | 14 | 5.8 | o — |
6 | 27 | 0 | ||
5 | 82 | 0 |
6 Ζ Ο Ο / Μ /d/dV
- 100
Table 2 (Cont’d)
Rate of Cmpd, Nq. Application1 | Percent Growth Inhibition2·3’4 | Pl505 | Percent Mortality6 cLCso7 | |
92 (cont.) | 4 | 93 | 15 | |
93 | 6 | 3 | 4.8 | 0 |
5 | 39 | 5 | ||
4 | 85 | 10 | ||
94 | 4 | 2 | .... | 0 |
95 | 4 | 13 | .... | 0 |
96 | 4 | -3 | 0 | |
97 | 4 | 29 | <4.0 | 0 |
98 | 4 | 7 | .... | o |
99 | 4 | -7 | 0 | |
100 | 5 | -6 | <4.0 | 0 |
4 | 33 | 0 | ||
101 | 4 | 17 | o | |
102 | 4 | 14 | 0 v..... | |
106 | 5 | -1 | 4.3 | o |
4 | 71 | 0 | ||
107 | 6 | 2 | 5.0 | o |
5 | 57 | 0 | ||
4 | 85 | 5 | ||
108 | 7 | 6 | 4.6 | o |
6 | 20 | 0 | ||
5 | 28 | 0 | ||
4 | 79 | 0 | ||
109 | 6 | -3 | 4.7 | o |
5 | 68 | 5 | ||
4 | 92 |
AP . 0 0 5 0 7
Table 2 (Cont'd)
Rate of Cmpd. No. ADDlication1 | Percent Growth Inhibition2·3·4 cl505 | Percent Mortality6 | pLC.507 | |
110 5 | 1 | <4.0 | 0 | |
4 | 43 | 5 | ||
111 5 | 5 | 4.3 | 0 | — |
4 | 68 | 10 | ||
112 6 | 24 | 5.6 | 0 | <4.0 |
5 | 85 | 20 | ||
4 | 97 | 25 | ||
113 7 | 17 | 6.5 | 0 | 5.2 |
6 | 86 | 10 | ||
5 | 98 | 60 | ||
4 | 98 | 55 | ||
114 6 | 10 | 5.2 | 0 | 4.2 |
5 | 69 | 25 | ||
4 | 97 | 55 | ||
115 7 | 28 | 6.4 | 0 | 4.4 |
6 | 68 | 5 | ||
5 | 97 | 35 | ||
4 | 99 | 60 | ||
116 7 | 27 | 6.4 | 0 | 5.4 |
6 | 65 | 5 | ||
5 | 99 | 80 | ||
4 | 100 | 95 | ||
117 7 | 29 | 6.4 | 0 | 4.5 |
6 | 70 | 0 | ||
5 | 95 | 20 | ||
4 | 100 | 75 | ||
118 7 | 23 | 6.1 | 0 | |
6 | 48 | 0 | ||
5 | 92 | 0 | ||
4 | 96 | 15 | ||
119 6 | 10 | 4.7 | 0 | .... |
5 | 39 | 0 | ||
4 | 75 | 15 |
AP/P/ 9 4 / 0 0 7 9 6
102
Table 2 (Cont’d)
CmDd. No. | Rate of Application1 | Percent Growth Inhibition2’3·4 | Cl505 | Percent Mortality6 | BLC507 |
121 | 7 | 6 | 6.2 | 0 | 4.6 |
6 | 76 | 0 | |||
5 | 97 | 35 | |||
4 | 99 | 70 | |||
122 | 6 | 40 | 5.8 | 0 | .... |
5 | 96 | 20 | |||
4 | 89 | 20 | |||
123 | 7 | 21 | 6.2 | 0 | <4.0 |
6 | 59 | 0 | |||
5 | 91 | 5 | |||
4 | 97 | 40 | |||
7 | 0 | 6.0 | 0 | — | |
6 | 61 | 0 | |||
5 | 91 | 0 | |||
4 | 97 | 5 | |||
124 | 6 | 7 | — | 0 | <4.0 |
5 | 96 | 25 | |||
4 | 97 | 35 | |||
8 | -16 | 6.2 | 0 | 4.5 | |
7 | 21 | 0 | |||
6 | 62 | 5 | |||
5 | 92 | 25 | |||
4 | 99 | 70 | |||
125 | 8 | 17 | 6.9 | 0 | 5.5 |
7 | 37 | 0 | |||
6 | 89 | 10 | |||
5 | 100 | 85 | |||
4 | 100 | 90 | |||
126 | 6 | -5 | 5.0 | 0 | .... |
5 | 57 | 0 | |||
4 | 96 | 20 |
ΛΡ . 0 0 5 o 7
103
Table 2 (Cont'd)
Cmpd, n.q. | Rate of Application1 | Percent Growth Inhibition2’3·4 | Pl505 | Percent Mortality6 | pLCso7 |
127 | 6 | 69 | >6.0 | 0 | <4.0 |
5 | 94 | 20 | |||
4 | 96 | 40 | |||
7 | 5 | 6.2 | 0 | 4.7 | |
6 | 77 | 10 | |||
5 | 96 | 40 | |||
4 | 99 | 70 | |||
128 | 7 | 22 | 6.6 | 5 | 4.6 |
6 | 85 | 15 | |||
5 | 96 | 25 | |||
4 | 99 | 70 | |||
129 | 7 | 44 | 6.8 | 0 | <4.0 |
6 | 76 | 15 | |||
5 | 97 | 25 | |||
4 | 98 | 45 | |||
130 | 5 | 6 | 4.4 | 0 | —- |
4 | 76 | 10 | |||
131 | 7 | 2 | 5.9 | 0 | .... |
6 | 54 | 0 | • | ||
5 | 85 | 0 | |||
4 | 94 | 20 | |||
132 | 7 | -8 | 6.0 | 0 | 4.4 |
6 | 60 | 15 | |||
5 | 92 | 25 | |||
4 | 99 | 70 | |||
133 | 7 | -1 | 5.8 | 0 | 4.0 |
6 | 31 | 5 | |||
5 | 91 | 20 | |||
4 | 96 | 50 | |||
134 | 6 | 13 | 5.3 | 0 | <4.0 |
5 | 78 | 5 | |||
4 | 98 | 35 |
AP/P/ 94/00796
Table 2 (ContcQ | ||||
Rate of | Percent Growth | Percent | ||
CmDd. No. | ADolication1 | Inhibition2·3·4 | Cl505 | Mortality* |
135 | 6 | -6 | 4.9 | 0 |
5 | 52 | 0 | ||
4 | 90 | 15 | ||
136 | 6 | 4 | 4.9 | 0 |
5 | 47 | 10 | ||
4 | 91 | 30 | ||
137 | 6 | 1 | 4.8 | 0 |
5 | 33 | 0 | ||
4 | 85 | 25 | ||
139 | 6 | 7 | 4.7 | 0 |
5 | 32 | 0 | ||
4 | 80 | 10 | ||
140 | 5 | 15 | 4.5 | 5 |
4 | 89 | 20 | ||
141 | 5 | 33 | 4.7 | 0 |
4 | 88 | 5 | ||
142 | 8 | 15 | 6.2 | 0 |
7 | 10 | 0 | ||
6 | 71 | 5 | ||
5 | 93 | 5 | ||
4 | 97 | 40 | ||
143 | 7 | 40 | 6.8 | 0 |
6 | 93 | 0 | ||
5 | 95 | 0 | ||
4 | 95 | 30 | ||
144 | 6 | -7 | 5.1 | 0 |
5 | 75 | 0 | ||
4 | 94 | 15 | ||
145 | 6 | 21 | 5.3 | 0 |
5 | 70 | 5 | ||
4 | 94 | 5 |
pLCSO7 <4.0 <4.0 <4.0.
<4.0
AP · Ο Ο 5 Ο 7
05
Table 2 (Cont'd)
CmDd. No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Ul505 | Percent Mortality6 | BLC507 |
146 | 7 | 0 | 6.0 | 0 | <4.0 |
6 | 60 | 0 | |||
5 | 89 | 20 | |||
4 | 97 | 40 | |||
147 | 6 | 5 | 5.2 | 0 | |
5 | 77 | 0 | |||
4 | 91 | 5 | |||
148 | 6 | 7 | 4.9 | 0 | |
5 | 43 | 0 | |||
4 | 84 | 0 | |||
174 | 5 | 23 | 4.6 | 0 | |
4 | 85 | 10 | |||
175 | 6 | 14 | 5.0 | 0 | .— |
5 | 53 | 0 | |||
4 | 80 | 0 | |||
177 | 8 | 11 | 6.7 | 0 | |
7 | 45 | 0 | |||
6 | 76 | 0 | |||
5 | 91 | 5 | |||
4 | 96 | 20 | |||
178 | 7 | 11 | 6.4 | 1 | 4.3 |
6 | 80 | 15 | |||
5 | 94 | 25 | |||
4 | 98 | 60 | |||
179 | 7 | -1 | 6.4 | 5 | 5.4 |
6 | 85 | 30 | |||
5 | 98 | 60 | |||
4 | 100 | 95 | |||
181 | 8 | 2 | 6.5 | 0 | <4.0 |
7 | 24 | 0 | |||
6 | 73 | 5 | |||
5 | 96 | 5 | |||
4 | 97 | 25 |
AP/P/ 9 4 / 0 0 7 9 6 c>
Table 2 (Cont'd)
CmDd. No. | Rate of Application1 | Percent Growth Inhibition2’3·4 | Pl505 | Percent Mortality6 |
182 | 8 | 11 | 6.4 | 0 |
7 | 25 | 0 | ||
6 | 63 | 0 | ||
5 | 92 | 0 | ||
4 | 95 | 5 | ||
183 | 7 | 31 | 6.6 | 0 |
6 | 82 | 15 | ||
5 | 97 | 35 | ||
4 | 100 | 85 | ||
184 | 7 | -3 | 5.9 | 0 |
6 | 43 | 0 | ||
5 | 92 | 15 | ||
4 | 95 | 20 | ||
185 | 7 | 7 | 6.2 | 0 |
6 | 72 | 20 | ||
5 | 95 | 25 | ||
4 | 98 | 50 | ||
186 | 7 | 30 | 6.1 | 0 |
6 | 47 | 0 | ||
5 | 86 | 5 | ||
4 | 96 | 10 | ||
? | 9 | 6.1 | 0 | |
6 | 65 | 0 | ||
5 | 92 | 0 | ||
4 | 96 | 25 | ||
7 | 14 | 5.9 | 0 | |
6 | 35 | 0 | ||
5 | 88 | 10 | ||
4 | 95 | 15 | ||
187 | 7 | 0 | 5.6 | 0 |
6 | 23 | 0 | ||
5 | 80 | 10 | ||
4 | 93 | 10 |
CLQ507 <4.0
4.9
3.9
AP.00507
107
Table 2 (Cont'd)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Cl505 | Percent Mortality6 | pLCso7 |
188 | 7 | 49 | 7.0 | 0 | 5.1 |
6 | 89 | 30 | |||
4 | 99 | 70 | |||
189 | 6 | -8 | 4.5 | 0 | <4.0 |
5 | 19 | 0 | |||
4 | 79 | 25 | |||
190 | 7 | 24 | 6.3 | 0 | |
6 | 65 | 10 | |||
5 | 93 | 0 | |||
4 | 96 | 15 | |||
191 | 7 | 42 | 6.8 | 0 | <4.0 |
6 | 85 | 10 | |||
5 | 95 | 10 | |||
4 | 97 | 40 | |||
192 | 7 | 15 | 6.5 | 5 | 5.1 |
6 | 86 | 20 | |||
5 | 98 | 60 | |||
4 | 100 | 75 | |||
193 | 7 | 16 | 6.2 | 0 | <4.0 |
6 | 64 | 0 | |||
5 | 90 | 20 | |||
4 | 96 | 30 | |||
194 | 7 | 19 | 6.3 | 0 | <4.0 |
6 | 76 | 5 | |||
5 | 92 | 15 | |||
4 | 97 | 25 | |||
195 | 7 | -3 | 6.1 | 0 | 4.9 |
6 | 67 | 5 | |||
5 | 96 | 45 | |||
4 | 98 | 90 |
AP/P/ 9 4 / 0 0 7 9 6 ’ OS
Table 2 (Cont'd)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Cl505 | Percent Mortality6 | CLO507 |
196 | 7 | 57 | .— | 0 | 4.8 |
6 | 90 | 15 | |||
5 | 95 | 30 | |||
4 | 100 | 85 | |||
9 | 1 | 7.1 | 0 | 5.2 | |
8 | 19 | 0 | |||
7 | 54 | 0 | |||
6 | 88 | 15 | |||
5 | 98 | 70 | |||
4 | 99 | 90 | |||
197 | 6 | 7 | 5.2 | 0 | <4.0 |
5 | 77 | 10 | |||
4 | 96 | 30 | |||
198 | 7 | -2 | 6.4 | 0 | 5.5 |
6 | 92 | 15 | |||
5 | 100 | 80 | |||
4 | 100 | 90 | |||
199 | 8 | 7 | 7.1 | 0 | 5.1: |
7 | 67 | 0 | |||
6 | 93 | 20 | |||
5 | 98 | 60 | |||
4 | 100 | 75 | |||
200 | 7 | -4 | 5.3 | 0 | |
6 | 26 | 0 | |||
5 | 64 | 0 | |||
4 | 88 | 5 | |||
201 | 7 | -6 | 5.6 | 0 | 4.8 |
6 | 15 | 0 | |||
5 | 93 | 25 | |||
4 | 97 | 95 | |||
202 | 8 | 8 | 6.2 | 0 | 4.4 |
7 | 18 | 0 | |||
6 | 66 | 5 | |||
5 | 95 | 30 | |||
4 | 97 | 65 |
AP. Ο Ο 5 Ο 7
09
Table ZIGont'd)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2'3’4 | P1505 | Percent Mortality® | Pk£507 |
203 | 6 | 6 | 4.5 | 0 | |
5 | 15 | 0 | |||
4 | 82 | 15 | |||
204 | 8 | 4 | 6.8 | 0 | 4.8 |
7 | 34 | 0 | |||
6 | 84 | 10 | |||
5 | 98 | 55 | |||
4 | 98 | 70 | |||
205 | 7 | 83 | 10 | -..- | |
6 | 97 | 65 | |||
5 | 100 | 90 | |||
4 | 100 | 95 | |||
8 | 12 | 7.2 | 0 | 6.2 | |
7 | 71 | 15 | |||
6 | 99 | 70 | |||
5 | 99 | 90 | |||
4 | 99 | 95 | |||
206 | 7 | 11 | 6.2 | 0 | <4.0 |
6 | 74 | 10 | |||
5 | 95 | 15 | |||
4 | 97 | 25 | |||
207 | 8 | 8 | 7.0 | 0 | <4.0 |
7 | 52 | 0 | |||
6 | 92 | 10 | |||
5 | 96 | 10 | |||
4 | 96 | 40 | |||
208 | 7 | 39 | 6.8 | 0 | <4.0 |
6 | 91 | 15 | |||
5 | 96 | 15 | |||
4 | 98 | 30 | |||
209 | 7 | 68 | .... | 0 | .... |
6 | 71 | 0 | |||
5 | 85 | 10 | |||
4 | 96 | 20 |
AP/P/ 9 4 / 0 0 7 9 6
1 ο
Table 2 (Cont’d)
Cmpd, No. | Rate of Application1 | Percent Growth Inhibition2·3’4 | Ol505 | Percent Mortality6 |
209 (cont.) | 9 | -1 | 6.7 | 0 |
6 | 22 | 0 | ||
7 | 37 | 0 | ||
6 | 70 | 0 | ||
5 | 87 | 0 | ||
4 | 96 | 5 | ||
210 | 9 | -4 | 7.0 | 0 |
8 | 8 | 0 | ||
7 | 55 | 10 | ||
6 | 92 | 25 | ||
5 | 100 | 75 | ||
4 | 100 | 85 | ||
211 | 7 | 14 | 6.2 | 0 |
6 | 69 | 0 | ||
5 | 90 | 5 | ||
4 | 97 | 40 | ||
213 | 7 | -4 | 6.4 | 0 |
6 | 80 | 15 | ||
5 | 97 | 65 | ||
4 | 100 | 95 | ||
214 | 8 | -3 | 6.8 | 0 |
7 | 33 | 0 | ||
6 | 90 | 25 | ||
5 | 100 | 95 | ||
4 | 100 | 100 | ||
215 | 7 | 2 | 6.4 | 0 |
6 | 88 | 25 | ||
5 | 98 | 50 | ||
4 | 100 | 80 | ||
216 | 6 | -10 | 4.8 | 0 |
5 | 37 | 0 | ||
4 | 90 | 45 |
GLC507
5.5 <4.0
5.2
5.8
5.1 <4.0
AP.00507
Table 2 (Cont'd)
Cmod. No. | Rate of Application1 | Percent Growth Inhibition2·3·4 | Pl505 | Percent Mortality6 | PLC507 |
217 | 7 | 1 | 6.1 | 0 | 4.3 |
6 | 73 | 0 | |||
5 | 95 | 20 | |||
4 | 97 | 60 | |||
218 | 7 | 8 | 6.5 | 0 | 5.6 |
6 | 87 | 20 | |||
5 | 100 | 90 | |||
4 | 100 | 95 | |||
219 | 7 | 43 | 6.9 | 5 | 5.9 |
6 | 96 | 45 | |||
5 | 100 | 90 | |||
4 | 100 | 95 | |||
220 | 7 | -4 | 5.5 | 0 | 4.1 |
6 | 24 | 0 | |||
5 | 76 | 15 | |||
4 | 97 | 55 | |||
221 | 4 | 2 | 0 | ||
222 | 5 | 3 | 4.4 | 0 | |
4 | 79 | 15 |
FOOTNOTES
1) The rate of application is expressed as the negative log of the molar concentration of the test compound in the diet.
2) Percent growth inhibition is derived from the total weight of insects (IW) at each rate of application in the test relative to the total weight of insects in an untreated control, % Gr. inh. = IW (control) - IWItest) X 100 IW (control)
3) ND = No data
4) A minus % growth inhibition indicates that the insects weighed more at the termination of the test than those in the untreated control.
12
5) pI50 is the negative log of the concentration of the test chemical that provides 50% growth inhibition of the test insects.
6) Percent mortality is derived from the number of dead insects (ID) relative to the total number of insects (Tl) used in the test, % Mortality = Tl - ID x 100 Tl
7) PLC50 is the negative log of the concentration of the test chemical that provides 50% mortality of the test insects.
AP. Ο Ο 5 Ο 7
1 3
Table 3
Insecticidal Activity of 2,4-diaminoquinazolines Applied as Foliar Sprays
Percent Mortality
Cmpd No. | Rate of ADDlication (ppm) | IfiW | BAW CJ_(1 | |
7 | 300 | 0 | ||
100 | 0 | |||
30 | 0 | |||
10 | 0 | |||
3 | 0 | |||
47 | 3000 | 80 | 100 | 85 |
1000 | 75 | 70 | 50 | |
300 | 16 | 20 | 35 | |
100 | 5 | 5 | 30 | |
30 | 5 | 0 | 20 | |
48 | 300 | 90 | 95 | 32 |
100 | 53 | 74 | 15 | |
30 | 6 | 5 | 0 | |
10 | 5 | 5 | 0 | |
49 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 95 | 100 | 100 | |
30 | 85 | 35 | 65 | |
10 | 32 | 5 | 40 | |
50 | 1000 | 65 | 100 | 100 |
300 | 44 | 95 | 95 | |
100 | 16 | 90 | 89 | |
30 | 16 | 50 | 5 | |
51 | 300 | 100 | 100 | 100 |
100 | 90 | 100 | 68 | |
30 | 80 | 95 | 20 | |
10 | 47 | 10 | 5 | |
52 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 95 | 100 | 100 | |
30 | 85 | 90 | 95 | |
10 | 44 | 20 | 45 |
AP/P/ 9 4/ 0 0 7 9 6
14
Table 3 (Cont'd)
Percent Mortality
Cmpd No, | Rate of ADDlication (ppm) | TBW | BAW | |
53 | 1000 | 100 | 100 | 85 |
300 | 100 | 100 | 85 | |
100 | 95 | 100 | 75 | |
30 | 85 | 90 | 35 | |
10 | 30 | 30 | 10 | |
54 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 95 | |
100 | 55 | 90 | 35 | |
30 | 32 | 40 | 28 | |
10 | 5 | 5 | 11 | |
60 | 1000 | 100 | 100 | 45 |
300 | 100 | 90 | 20 | |
100 | 95 | 40 | 5 | |
30 | 89 | 5 | 10 | |
10 | 24 | 0 | 15 | |
61 | 1000 | 100 | 100 | 65 |
300 | 100 | 100 | 35 | |
100 | 100 | 85 | 35 | |
30 | 94 | 70 | 5 | |
10 | 95 | 10 | 15 | |
63 | 3000 | 100 | 100 | 100 |
1000 | 100 | 100 | 100 | |
300 | 100 | 100 | 95 | |
100 | 100 | 95 | 100 | |
30 | 95 | 85 | 95 | |
66 | 1000 | 95 | 100 | 100 |
300 | 90 | 100 | 100 | |
100 | 90 | 100 | 100 | |
30 | 40 | 100 | 74 | |
10 | 11 | 40 | 75 | |
67 | 3000 | 17 | 26 | 25 |
1000 | 5 | 10 | 5 | |
300 | 5 | 5 | 0 | |
100 | 0 | 0 | 0 | |
30 | 5 | 0 | 11 |
AP. 0 0 5 0 7 ! ~
Table 3 (Cont'd)
Percent Mortality
Cmpd No, | Rate of Application (ppm) | TBW | SAW | CL<1) |
68 | 3000 | 0 | 10 | 10 |
1000 | 0 | 5 | 6 | |
300 | 5 | 0 | 0 | |
100 | 0 | 0 | 11 | |
30 | 0 | 0 | 5 | |
69 | 3000 | 5 | 45 | 25 |
1000 | 0 | 0 | 11 | |
300 | 0 | 0 | 5 | |
100 | 0 | 0 | 10 | |
30 | 0 | 0 | 0 | |
70 | 3000 | 0(11) | 0(0) | 10(32) |
1000 | 0 (0) | 0(5) | 15(25) | |
300 | 0(10) | 0(0) | 10(20) | |
100 | 0 (0) | 0(0) | 0(20) | |
30 | 5 (0) | 0(0) | 11 (21) | |
71 | 1000 | 5 | 0 | 15 |
300 | 0 | 0 | 21 | |
100 | 0 | 0 | 10 | |
30 | 0 | 0 | 5 | |
10 | 5 | 0 | 15 | |
72 | 3000 | (70) | (¢0) | |
1000 | 21 (63) | 0 | 45 (35) | |
300 | 6 (5) | 0 | 15(17) | |
100 | 5 (0) | 0 | 5(10) | |
30 | 0 (0) | 0 | 5(10) | |
10 | 0 | 0 | 10 | |
73 | 3000 | 100 | 100 | 95 |
1000 | 100 | 100 | 75 | |
300 | 80 | 90 | 47 | |
100 | 47 | 50 | 45 | |
30 | 10 | 5 | 26 | |
74 | 3000 | 25 | 16 | 15 |
1000 | 5 | 0 | 5 | |
300 | 0 | 0 | 15 | |
100 | 5 | 0 | 15 | |
30 | 0 | 0 | 5. |
AP/P; 9 4/ 0 0 7 9 6
16
Table 3 (Cont’d)
Percent Mortality
Cmpd Nq, | Rate of Application (ppm) | IB& | BAW | £1.(1) |
80 | 1000 | 90 | ||
300 | 58 | |||
100 | 0 | |||
82 | 1000 | 100 | ||
300 | 95 | |||
100 | 90 | |||
30 | 39 | |||
10 | 7 | |||
3 | 0 | |||
88 | 1000 | 95 | ||
300 | 40 | |||
100 | 5 | |||
90 | 1000 | 0 | ||
300 | 0(35) | |||
100 | 0 (0) | |||
30 | (0) | |||
10 | (0) | |||
3 | (0) | |||
92 | 3000 | 100 | 10 | 58 |
1000 | 100 | 0 | 37 | |
300 | 90 | 0 | 26 | |
100 | 30 | 0 | 30 | |
30 | 5 | 0 | 11 | |
93 | 1000 | 20 | 0 | 25 |
300 | 0 | 0 | 15 | |
100 | 0 | 0 | 16 | |
30 | 10 | 0 | 11 | |
10 | 0 | 0 | 5 | |
107 | 3000 | 100 | 95 | 100 |
1000 | 95 | 78 | 79 | |
300 | 53 | 21 | 45 | |
100 | 5 | 5 | 10 | |
30 | 0 | 10 | 5 |
AP.0 0 5 0 7
1 7
Table 3 (Cont'dl
Percent Mortality
Cmpd Ncl | Rate of Application (ppm) | IBYY | BAW | £L<1> |
108 | 3000 | 53 | 95 | 75 |
1000 | 17 | 50 | 26 | |
300 | 5 | 5 | 10 | |
100 | 5 | 0 . | 0 | |
30 | 0 | 0 | 5 | |
109 | 3000 | 100 | 83 | 100 |
1000 | 90 | 59 | 84 | |
300 | 84 | 10 | 85 | |
100 | 6 | 16 | 35 | |
30 | 0 | 0 | 10 | |
111 | 3000 | 56 | 95 | 41 |
1000 | 20 | 35 | 26 | |
300 | 17 | 5 | 5 | |
100 | 5 | 0 | 5 | |
30 | 0 | 0 | 0 | |
112 | 1000 | 100 | 100 | 95 |
300 | 100 | 5 | 75 | |
100 | 78 | 5 | 58 | |
30 | 41 | 0 | 20 | |
10 | 5 | 0 | 24 | |
1000 | 95 | |||
300 | 63 | |||
100 | 30 | |||
30 | 0 | |||
10 | 0 |
96Z00/V6 /d/dV
Table 3 (Cont'd)
Cmpd No,
113
R
Γ (
114
115 . $ c
116
Percent Mortality
Rate of Application (ppm) | IEW | BAW | clO) |
1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 |
100 | 100 | 95 | 94 |
30 | 100 | 29 | 60 |
10 | 80 | 5 | 58 |
100 | 100 | 95 | |
30 | 90 | 83 | |
10 | 37 | 50 | |
3 | 5 | 11 | |
1 | 5 | 0 | |
3000 | 100 | 100 | 100 |
1000 | 100 | 95 | 75 |
300 | 95 | 85 | 90 |
100 | 80 | 10 | 75 |
30 | 5 | 0 | 45 |
1000 | 100 | 100 | 100 |
300 | 100 | 90 | 85 |
100 | 95 | 22 | 90 |
30 | 89 | 5 | 85 |
10 | 29 | 5 | 25 |
1000 | 100 | ||
300 | 95 | ||
100 | 50 | ||
30 | 5 | ||
10 | 0 | ||
1000 | 100 | 100 | 100 |
300 | 100 | 100 | 94 |
100 | 95 | 95 | 95 |
30 | 89 | 90 | 65 |
10 | 18 | 28 | 10 |
100 | 100 | 100 | 85 |
30 | 95 | 85 | 63 |
10 | 30 | 20 | 20 |
3 | 5 | 5 | 15 |
1 | 0 | 0 | 15 |
AP .0 0 5 0 7
1 9
Table 3 (Cont’d)
Percent Mortality
Cmpd N& | Rate of Application (ppm) | Iffifli | BAW | 0.0) |
117 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 9σ | |
100 | 95 | 95 | 90 | |
30 | 75 | 60 | 84 | |
10 | 40 | 5 | 58 | |
100 | 90 | |||
30 | 100 | |||
10 | 100 | |||
3 | 15 | |||
1 | 0 | |||
118 | 1000 | 100 | 100 | 83 |
300 | 100 | 95 | 89 | |
100 | 100 | 35 | 61 | |
30 | 40 | 21 | 28 | |
10 | 17 | 0 | 6 | |
100 | 100 | |||
30 | 72 | |||
10 | 21 | |||
3 | 5 | |||
1 | 0 | |||
121 | 1000 | 100 | 100 | ’90 |
300 | 100 | 100 | 95 | |
100 | 82 | 100 | 95 | |
30 | 70 | 95 | 90 | |
10 | 37 | 15 | 95 | |
122 | 1000 | 100 | 95 | 71 |
300 | 83 | 40 | 44 | |
100 | 53 | 10 | 5 | |
30 | 16 | 0 | 6 | |
10 | 0 | 0 | 0 | |
123 | 1000 | 80 | 90 | 70 |
300 | 89 | 55 | 55 | |
100 | 55 | 30 | 30 | |
30 | 20 | 5 | 0 | |
10 | 5 | 0 | 5 |
AP/P/ 9 4 / 0 0 7 9 6
20
Table 3 (Cont'd)
Percent Mortality
CmDd No. | Rate of Application (ppm) | IEW | BAW | £Ld) |
124 | 1000 | 95 | 85 | 100 |
300 | 95 | 37 | 83 | |
100 | 74 | 5 | 75 | |
30 | 47 | 0 | 25 | |
10 | 25 | 0 | 5 | |
125 | 100 | 95 | 95 | 100 |
30 | 95 | 55 | 95 | |
10 | 37 | 16 | 28 | |
3 | 5 | 0 | 5 | |
1 | 0 | 5 | 0 | |
100 | 100 | |||
30 | 90 | |||
10 | 20 | |||
3 | 5 | |||
1 | 5 | |||
126 | 1000 | 100 | 95 | 90 |
300 | 80 | 79 | 90 | |
100 | 16 | 5 | 37 | |
30 | 5 | 0 | 10 | |
10 | 5 | 0 | 5 | |
300 | 100 | 70 | 100 | |
100 | 70 | 5 | 85 | |
30 | 24 | 0 | 85 | |
10 | 11 | 0 | 47 | |
3 | 0 | 0 | 20 | |
100 | 100 | |||
30 | 95 | |||
10 | 72 | |||
3 | 30 | |||
1 | 0 | |||
127 | 1000 | 85 | 85 | 100 |
300 | 65 | 55 | 65 | |
100 | 45 | 10 | 50 | |
30 | 5 | 0 | 15 | |
10 | 0 | 0 | 0 |
Table 3 (Cont'd)
Cmpd No,
128
129 r
C 131
132 .· 133
I o
134
135
AP.00507
2 1
Percent Mortality
Rate of App-ltgatjon (ppm.) | TBW | BAW | CLd) |
1000 | 100 | 100 | 100 |
300 | 100 | 100 | 90 |
100 | 95 | 95 | 65 |
30 | 85 | 47 | 40 |
10 | 40 | 25 | 5 |
1000 | 100 | 100 | 100 |
300 | 95 | 95 | 95 |
100 | 74 | 50 | 85 |
30 | 25 | 5 | 95 |
10 | 0 | 0 | 35 |
1000 | 100 | 85 | 95 |
300 | 95 | 75 | 95 |
100 | 95 | 20 | 70 |
30 | 60 | 0 | 40 |
10 | 5 | 0 | 20 |
1000 | 100 | 100 | 100 |
300 | 100 | 100 | 84 |
100 | 95 | 95 | 95 |
30 | 80 | 25 | 90 |
10 | 25 | 5 | 15 |
1000 | 100 | 100 | 100 |
300 | 100 | 95 | 100 |
100 | 95 | 80 | 95 |
30 | 78 | 15 | 37 |
10 | 32 | 5 | 5 |
3000 | 100 | 100 | 100 |
1000 | 100 | 95 | 95 |
300 | 95 | 44 | 84 |
100 | 63 | 5 | 40 |
30 | 16 | 0 | 5 |
1000 | 100 | 15 | 35 |
300 | 70 | 0 | 15 |
100 | 15 | 0 | 5 |
30 | 5 | 0 | 5 |
10 | 5 | 10 | 7 |
AP/P/ 9 4 / 0 0 7 9 6
122
Table 3 (Cont'd)
Percent Mortality
Cmpd No, | Rate of Application (ppm) | TBW | BAW | £L<1) |
136 | 1000 | 29 | 0 | 58 |
300 | 10 | 0 | 5 | |
100 | 0 | 5 | 15 | |
30 | 0 | 5 | 15 | |
10 | 0 | 0 | 10 | |
137 | 3000 | 50 | 0 | 42 |
1000 | 0 | 0 | 20 | |
300 | 0 | 0 | 0 | |
100 | 0 | 5 | 10 | |
30 | 0 | 0 | 10 | |
140 | 3000 | 74 | 58 | 20 |
1000 | 56 | 15 | 5 | |
300 | 5 | 15 | 5 | |
100 | 0 | 10 | 0 | |
30 | 0 | 0 | 0 | |
141 | 3000 | 16 | 5 | 0 |
1000 | 10 | 10 | 0 | |
300 | 11 | 0 | 0 | |
100 | 0 | 0 | 10 | |
30 | 0 | 0 | 0 | |
142 | 300 | 100 | 70 | 100 |
100 | 70 | 5 | 85 | |
30 | 24 | 0 | 85 | |
10 | 11 | 0 | 47 | |
3 | 0 | 0 | 20 | |
100 | 100 | |||
30 | 95 | |||
10 | 72 | |||
3 | 30 | |||
1 | 0 | |||
143 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 100 | 100 | 89 | |
30 | 100 | 100 | 90 | |
10 | 44 | 67 | 85 |
AP.00507
123
Table 3 (Coat'd)
Percent Mortality
CmpdNflx | Rate of Application (oom) | IBW | BAW | £L<1> |
143 (cont.) | 100 | 100 | 100 | 95 |
30 | 90 | 95 | 90 | |
10 | 85 | 70 | 95 | |
3 | 19 | 5 | 45 | |
1 | 0 | 0 | 5 | |
100 | 100 | 100 | ||
30 | 95 | 89 | ||
10 | 79 | 70 | ||
3 | 10 | 15 | ||
1 | 0 | 0 | ||
144 | 3000 | 11 | 40 | 65 |
1000 | 10 | 0 | 55 | |
300 | 0 | 0 | 5 | |
100 | 0 | 0 | 10 | |
30 | 0 | 0 | 5 | |
146 | 1000 | 95 | 95 | 90 |
300 | 94 | 70 | 85 | |
100 | 90 | 5 | 20 | |
30 | 89 | 0 | 5 | |
10 | 0 | 0 | 0 | |
174 | 3000 | 5 | ||
1000 | 11 | |||
300 | 5 | |||
100 | 0 | |||
30 | 5 | |||
175 | 1000 | 89 | ||
300 | 35 | |||
100 | 10 | |||
30 | 5 | |||
10 | 0 | |||
177 | 300 | 95 | 100 | 60 |
100 | 80 | 95 | 32 | |
30 | 58 | 60 | 45 | |
10 | 28 | 5 | 35 | |
3 | 5 | 0 | 5 |
AP/P/ 94/00796
124
Table 3 (Coord)
Percent Mortality
Cmpd No. | Rate of Application (ppm) | IEW | BAW | £L0) | |
177 (cont.) | 300 | 100 | 100 | 90 | |
100 | 95 | 95 | 95 | ||
30 | 53 | 90 | 60 | ||
10 | 21 | 6 | 45 | ||
3 | 0 | 5 | 10 | ||
178 | 1000 | 100 | 100 | 100 | |
C· | 300 | 100 | 100 | 80 | |
100 | 95 | 95 | 79 | ||
30 | 84 | 63 | 47 | ||
c | 10 | 56 | 30 | 50 | |
300 | 80 | ||||
100 | 100 | 75 | |||
30 | 100 | 90 | |||
10 | 90 | 90 | |||
3 | 32 | 5 | |||
1 | 6 | ||||
179 | 100 | 100 | 95 | 100 | |
30 | 65 | 63 | 95 | ||
10 | 53 | 5 | 40 | ||
3 | 5 | 0 | 10 | ||
1 | 0 | 0 | 0 | ||
181 | 1000 | 100 | 95 | 74 | |
300 | 90 | 20 | 75 | ||
o | 100 | 79 | 10 | 50 | |
30 | 28 | 0 | 5 | ||
10 | 11 | 0 | 10 | ||
182 | 1000 | 100 | 90 | 100 | |
300 | 83 | 32 | 95 | ||
100 | 53 | 5 | 75 | ||
30 | 35 | 0 | 85 | ||
10 | 5 | 0 | 37 | ||
183 | 1000 | 100 | 100 | 100 | |
300 | 100 | 100 | 100 | ||
100 | 95 | 90 | 100 | ||
30 | 89 | 55 | 95 | ||
10 | 53 | 15 | 90 |
Table 3 (Cont'dl c>
AP.0 0 5 0 7
125
Rate of
Application (ppm)
Percent Mortality
Gmcd-No.
TBW fiAW £1.0)
183 (cont.) | 100 30 10 3 1 | 95 84 59 5 0 | 80 42 45 10 5 | |
184 | 1000 | 95 | 39 | 79 |
300 | 72 | 5 | 10 | |
100 | 45 | 0 | 5 | |
30 | 5 | 0 | 0 | |
10 | 0 | 0 | 0 | |
185 | 1000 | 100 | 100 | 90 |
300 | 100 | 89 | 80 | |
100 | 80 | 55 | 25 | |
30 | 11 | 15 | 0 | |
10 | 6 | 16 | 5 | |
186 | 1000 | 100 | 75 | 89 |
300 | 72 | 20 | 55 | |
100 | 67 | 5 | 11 | |
30 | 35 | 0 | 10 | |
10 | 5 | 0 | 0 | |
188 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 100 | 100 | 100 | |
30 | 95 | 85 | 84 | |
10 | 71 | 65 | 55 | |
100 | 100 | 100 | 80 | |
30 | 95 | 95 | 58 | |
10 | 71 | 37 | 60 | |
3 | 6 | 5 | 5 | |
1 | 6 | 0 | 0 | |
189 | 300 | 5 | 95 | 70 |
100 | 0 | 44 | 20 | |
30 | 0 | 5 | 11 | |
10 | 11 | 5 | 0 | |
3 | 5 | 0 | 10 |
6 Z 0 0 / 7 6 /d/dV
126
Table 3 (Cont’d)
Rate of
Cmpd No, Application (ppm)
Percent Mortality
IBW £jJ1)
189 (cont.)
3000 | 84 |
1000 | 39 |
300 | 10 |
100 | 0 |
30 | 0 |
190
191
192
193
1000 | 100 | 95 | 100 |
300 | 100 | 58 | 70 |
100 | 95 | 5 | 85 |
30 | 50 | 0 | 45 |
10 | 11 | 0 | 5 |
3000 | 100 | 100 | 100 |
1000 | 100 | 100 | 100 |
300 | 95 | 100 | 100 |
100 | 100 | 100 | 90 |
30 | 85 | 80 | 85 |
100 | 89 | 95 | 100 |
30 | 67 | 56 | 95 |
10 | 22 | 5 | 20 |
3 | 21 | 0 | 0 |
1 | 0 | 0 | 0 |
300 | 100 | 100 | 100 |
100 | 95 | 95 | 95 |
30 | 30 | 42 | 74 |
10 | 5 | 5 | 40 |
3 | 5 | 0 | 5 |
1000 | 100 | 100 | 85 |
300 | 90 | 95 | 85 |
100 | 89 | 83 | 85 |
30 | 22 | 90 | 25 |
10 | 0 | 10 | 5 |
1000 | 100 | 100 | 100 |
300 | 83 | 100 | 100 |
100 | 44 | 100 | 95 |
30 | 5 | 80 | 55 |
10 | 0 | 45 | 15 |
194
AP . 0 0 5 0 7
127
Table 3 (Cont'd)
Percent Mortality
CmcsLMfix | Rate of Application (ppm) | BAW | £1.(1) | |
194 (cont.) | 300 | 95 | 100 | 100 |
100 | 67 | 100 | 90 | |
30 | 10 | 90 | 79 | |
10 | 6 | 44 | 20 | |
3 | 0 | 5 | 0 | |
195 | 1000 | 95 | 47 | 15 |
300 | 61 | 26 | 20 | |
100 | 11 | 15 | 15 | |
30 | 0 | 0 | 10 | |
10 | 0 | 0 | 5 | |
196 | 3000 | 100 | 100 | 100 |
1000 | 100 | 100 | 100 | |
300 | 100 | 100 | 80 | |
100 | 100 | 100 | 65 | |
30 | 83 | 53 | 75 | |
100 | 95 | 95 | 95 | |
30 | 80 | 6 | 35 | |
10 | 5 | 5 | 11 | |
3 | 0 | 0 | 0 | |
1 | 6 | 0 | 5 | |
197 | 1000 | 25 | 5 | 25 |
300 | 5 | 5 | 0 | |
100 | 0 | 0 | 0 | |
30 | 0 | 0 | 0 | |
10 | 0 | 0 | 0 | |
700 | 21 | 16 | 60 | |
100 | 5 | 5 | 0 | |
30 | 0 | 0 | 5 | |
10 | 0 | 0 | 0 | |
3 | 0 | 5 | 10 | |
198 | 300 | 100 | 100 | 65 |
100 | 95 | 100 | 60 | |
30 | 53 | 0 | 37 | |
10 | 33 | 5 | 5 | |
3 | 0 | 0 | 5 |
iwr>! 94 / 00796
128
Table 3 (Cont'd)
Cmpd No,
198 (cont.)
199 c
200 c
o
201
202
Percent Mortality
Rate of Application (ppm) | TBW | BAW | clO) |
300 | 95 | - | |
100 | 68 | ||
30 | 11 | ||
10 | 0 | ||
3 | 7 | ||
300 | 100 | 100 | 95 |
100 | 100 | 100 | 67 |
30 | 95 | 95 | 58 |
10 | 68 | 25 | 30 |
3 | 6 | 5 | 0 |
3000 | 95 | 100 | 100 |
1000 | 79 | 100 | 95 |
300 | 50 | 95 | 79 |
100 | 5 | 68 | 75 |
30 | 0 | 15 | 60 |
1000 | 100 | ||
300 | 95 | ||
100 | 95 | ||
30 | 80 | ||
10 | 55 | ||
100 | 75 | ||
30 | 75 | ||
10 | 25 | ||
3 | 20 | ||
1 | 15 | ||
1000 | 95 | 95 | 55 |
300 | 53 | 45 | 45 |
100 | 5 | 20 | 25 |
30 | 0 | 0 | 5 |
10 | 5 | 11 | 10 |
30 | 6 | 0 | 55 |
3 | 21 | 0 | 5 |
A λ c Π 1 ftp . υ υ □ υ ι
129
Table 31Cont’d)
Percent Mortality
Cmpd No, | Rate of Application (ppm) | TfiW | z&u | CLO) |
204 | 30 | 65 | 20 | 100 |
3 | 10 | 5 | 25 | |
300 | 100 | 100 | 90 | |
100 | 94 | 95 | 73 | |
30 | 89 | 24 | 85 | |
10 | 40 | 26 | 80 | |
3 | 5 | 0 | 25 | |
205 | 100 | 100 | 95 | 50 |
30 | 100 | 75 | 5 | |
10 | 78 | 5 | 0 | |
3 | 25 | 0 | 6 | |
1 | 18 | 0 | 5 | |
300 | 100 | 100 | 95 | |
100 | 95 | 100 | 40 | |
30 | 90 | 85 | 5 | |
10 | 70 | 32 | 5 | |
3 | 10 | 5 | 5 | |
206 | 1000 | 100 | 100 | 94 |
300 | 89 | 100 | 85 | |
100 | 90 | 100 | 26 | |
30 | 53 | 100 | 25 | |
10 | 11 | 60 | 35 | |
207 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 100 | 100 | 100 | |
30 | 94 | 100 | 95 | |
10 | 63 | 100 | 22 | |
100 | 100 | 100 | ||
30 | 94 | 100 | ||
10 | 40 | 95 | ||
3 | 7 | 13 | ||
1 | 5 | 0 |
AP/P/ 9 4/ 0 0 7 9 6
130
Table 3 (Contd)
Percent Mortality
Cmpd Nq, | Rate of Application (ppm) | IfiYY | BAW | clO) |
208 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 95 | 100 | 90 | |
30 | 80 | 95 | 70 | |
10 | 35 | 55 | 80 | |
300 | 100 | |||
100 | 100 | 100 | 100 | |
30 | 95 | 79 | 80 | |
10 | 59 | 25 | 70 | |
3 | 11 | 5 | 5 | |
1 | 0 | 5 | 0 | |
300 | 100 | 100 | ||
100 | 100 | 100 | 95 | |
30 | 95 | 95 | 65 | |
10 | 90 | 45 | 76 | |
3 | 19 | 5 | 16 | |
1 | 11 | 5 | 10 | |
100 | 100 | 95 | ||
30 | 89 | 80 | ||
10 | 26 | 85 | ||
3 | 10 | 5 | ||
1 | 0 | 0 | ||
209 | 300 | 95 | 95 | 74 |
100 | 35 | 42 | 25 | |
30 | 5 | 5 | 20 | |
10 | 0 | 10 | 15 | |
3 | 0 | 0 | 15 | |
300 | 70 | 79 | 84 | |
100 | 16 | 60 | 63 | |
30 | 5 | 5 | 10 | |
10 | 5 | 16 | 20 | |
3 | 0 | 10 | 5 | |
300 | 90 | 80 | 85 | |
100 | 50 | 53 | 84 | |
30 | 16 | 10 | 10 | |
10 | 0 | 5 | 5 |
AP . 0 0 5 0 7
131
Table 3 (Cont'd)
Percent Mortality
Rate of
OmcdlkL | AcpiicaliprUcam) | IBSfli | BAW | CLd) | |
209 (cont.) | 3 | 5 | 0 | 0 | |
1 | 0 | 5 | 5 | ||
210 | 100 | 95 | 100 | 84 | |
30 | 100 | 100 | 95 | ||
10 | 50 | 95 | 95 | ||
3 | 21 | 50 | 70 | ||
1 | 5 | 5 | 22 | ||
o | 100 | 100 | 100 | 95 | |
30 | 90 | 100 | 95 | ||
10 | 71 | 95 | 80 | ||
3 | 29 | 25 | 80 | ||
1 | 0 | 5 | 5 | ||
211 | 30 | 30 | 56 | 80 | |
3 | 11 | 5 | 5 | ||
300 | 95 | 100 | 80 | ||
100 | 80 | 94 | 80 | ||
30 | 21 | 78 | 75 | ||
10 | 5 | 11 | 55 | ||
3 | 0 | 0 | 10 | ||
c | 213 | 300 | 100 | 95 | |
V. | 100 | 95 | 85 | 35 | |
30 | 85 | 30 | 15 | ||
r , | 10 | 6 | 21 | 20 | |
3 | 0 | 0 | 5 | ||
1000 | 75 | ||||
300 | 47 | ||||
100 | 44 | ||||
30 | 10 | ||||
10 | 5 | ||||
214 | 100 | 95 | 95 | 74 | |
30 | 75 | 75 | 68 | ||
10 | 11 | 10 | 21 | ||
3 | 0 | 10 | 5 | ||
1 | 0 | 0 | 5 |
AP/P/ 9 4 / 0 0 7 9 6
132
Table 3 (Cont'd)
Percent Mortality
Cmpd No, | Rate of Application (ppm) | IBW | BAW | CU1) |
215 | 1000 | 100 | 100 | 100 |
300 | 100 | 100 | 100 | |
100 | 95 | 95 | 90 | |
30 | 69 | 65 | 37 | |
10 | 7 | 10 | 5 | |
216 | 100 | 0 | 26 | 15 |
30 | 0 | 0 | 5 | |
10 | 6 | 0 | 5 | |
3 | 5 | 11 | 10 | |
1 | 0 | 21 | 21 | |
217 | 1000 | 100 | 100 | 84 |
300 | 95 | 95 | 53 | |
100 | 69 | 28 | 25 | |
30 | 6 | 5 | 0 | |
10 | 0 | 0 | 0 | |
218 | 300 | 100 | 100 | 100 |
100 | 100 | 100 | 100 | |
30 | 95 | 75 | 89 | |
10 | 75 | 50 | 95 | |
. | 3 | 33 | 5 | 15 |
• • 219 | 100 | 100 | 100 | 100 |
30 | 100 | 95 | 85 | |
10 | 79 | 15 | 79 | |
3 | 5 | 5 | 5 | |
1 | 5 | 0 | 16 | |
1) TBW, BAW, and Cl are, respectively, the above-described tobacco budworm, beet armyworm, and cabbage looper.
Claims (2)
- ι . A substituted diaminoquinazoline compound characterized by the formula;C 20 whereinR1 is hydrogen or lower alkyl;R2 is hydrogen, lower alkyl, lower alkylcarbonyl, or lower aikoxycarbonyl; or R1 and R2, taken together, form the group -R6-O-R®, wherein R6 is lower alkylene;R® is hydrogen;R7 is hydrogen, lower alkylcarbonyl, or lower aikoxycarbonyl;W is selected from hydrogen, halogen, lower alkyl, lower haloalkyi, phenyl, and phenyl substituted with lower alkyl or lower haloalkyi, with the proviso that when X is phenyl, W is other than hydrogen;Y and Z are selected from hydrogen, halogen, and phenyl; andAP/P/ 9 4/ 0 0 7 9 6X is selected from (a) phenyl;(b) aryl substituted with one or more of halogens, lower alkyl, lower haloalkyi, lower alkoxy, lower alkylthio, lower alkylsulfonyl, formyl, lower aikoxycarbonyl, phenyl or phenyl substituted with one or more halogens or lower haloalkyi, phenoxy or phenoxy substituted with one134 or more halogens, lower haloalkoxy, lower alkoxyalkyl, carboxy, cyano, nitro, aminocarbonyl, lower alkylcarbonylamino, lower alkylsulfonylamino;or substituted phenyl of the formulaOR3Ci ίc.(c.wherein R3 is hydrogen; alkyl; tri(lower alkyl)silylaJkyi; (4-halophenyl)lower alkyl; pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-alkylsulfonylphenoxy)alkyl;(c) naphthyl;(d) thienyl or thienyl substituted with halogen, lower alkyl, or haloalkyl;(e) aroyl, or substituted aroyl of the formula:c cwherein V’, W’, X’, Y', and Z’ are independently selected from hydrogen, halogen, haloalkyl, cyano, carboxy, lower alkoxycarbonyl, and phenyl substituted with halogen or haloalkyl;(f) (aryl)(halo)alkenyl of the formula:rCC 20 cAP . 0 0 5 0 7135 wherein V”, W”, X, Y”, and Z” are independently selected from hydrogen, halogen, lower alkyl, lower haloalkyl, cyano, carboxy, lower alkoxycarbonyl, and aminocarbonyl;(g) 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran4-yl; 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro2,2-dimethyl-3-benzofuranon-4-yl.
- 2 The compound of claim 23 characterized in that X is phenyl substituted with chloro, trifluoromethyl, or (aryl)(halo)alkenyl compounds of the formula where V”, W”, X”, Y”, and Z” are independently selected from hydrogen, trifluoromethyl, or 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 5halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2-dim,ethyl-3benzofuranon-4-yl.3 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(3,5-di(trifluoromethyl)phenyl]quinazoline.< The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline.5 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-[1 -chloro-2-(4-trifluoromethylphenyl)ethenyl]-quinazoline.θ The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline.AP/P/ 9 4 / 0 0 7 9 6136 ' 7 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2 ylmethoxy)phenyl]quinazoiine.8 The compound of claim 23 characterized in that the 5 diaminoquinazoline is 2,4-diamino-5-methyl-6-(5-chlorothien-2yl)quinazoline.9 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(4-trifluoromethylphenylcarbonyl)quinazoline.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1938993A | 1993-02-18 | 1993-02-18 | |
US14949193A | 1993-11-09 | 1993-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9600796A0 AP9600796A0 (en) | 1996-04-30 |
AP507A true AP507A (en) | 1996-07-18 |
Family
ID=26692173
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1994/000620A AP506A (en) | 1993-02-18 | 1994-02-16 | Insecticidal substituted-2,4-diaminoquinazolines. |
APAP/P/1996/000796A AP507A (en) | 1993-02-18 | 1996-02-16 | Novel insecticidal 2,4-diaminoquinazolines. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1994/000620A AP506A (en) | 1993-02-18 | 1994-02-16 | Insecticidal substituted-2,4-diaminoquinazolines. |
Country Status (10)
Country | Link |
---|---|
US (3) | US5534518A (en) |
EP (1) | EP0684824A4 (en) |
AP (2) | AP506A (en) |
AU (1) | AU6298694A (en) |
IL (1) | IL108630A0 (en) |
MA (1) | MA23116A1 (en) |
MX (1) | MX9401249A (en) |
TN (1) | TNSN94014A1 (en) |
TW (1) | TW315298B (en) |
WO (1) | WO1994018980A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR012634A1 (en) * | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
JP4370002B2 (en) * | 1997-08-08 | 2009-11-25 | 富山化学工業株式会社 | Quinolone carboxylic acid derivative or salt thereof |
MY122278A (en) * | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
US7030109B2 (en) | 1999-07-19 | 2006-04-18 | Pharmacia & Upjohn Company | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
BRPI0112121B1 (en) * | 2000-06-30 | 2015-09-01 | Basf Ag | Process for preparing 4-bromoaniline derivatives |
PE20020506A1 (en) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS |
CA2439463A1 (en) * | 2001-02-28 | 2002-09-06 | Anders Hallberg | Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
DK1474395T3 (en) * | 2002-02-12 | 2008-02-11 | Smithkline Beecham Corp | Nicotinamide derivatives useful as p38 inhibitors |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
CA2516942A1 (en) * | 2003-02-04 | 2004-08-19 | Mcmaster University | Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reduxtase; screening assay for the identification of novel therapeutics and their cellular targets |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
MXPA05011103A (en) * | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Quinazoline compounds useful as p38 kinase inhibitors. |
US20040248880A1 (en) * | 2003-04-25 | 2004-12-09 | Jacobsen Eric Jon | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position |
US7465738B2 (en) * | 2003-06-16 | 2008-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as promoters of SMN2 |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
EP1765810B1 (en) | 2004-06-08 | 2016-08-17 | Families of Spinal Muscular Atrophy | 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy |
WO2006029385A2 (en) * | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
WO2006050843A1 (en) * | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Aminoquinazolines compounds |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
CA2659376C (en) | 2006-08-01 | 2014-10-14 | Jasbir Singh | 2,4-diaminoquinazolines for spinal muscular atrophy |
US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
MX2010010998A (en) * | 2008-04-07 | 2011-01-25 | Chelsea Therapeutics Inc | Antifolate compositions. |
DE102008022221A1 (en) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitors of human aldosterone synthase CYP11B2 |
AU2010270596A1 (en) * | 2009-07-08 | 2012-02-02 | Chelsea Therapeutics, Inc. | Stable crystalline polymorphs of the dipotassium salt of (S) -2- {4- [2- (2, 4-diamino-quinazolin-6-yl) -ethyl] -benzoylamino} -4-methylene-pentanedioic acid |
JP2013510163A (en) * | 2009-11-06 | 2013-03-21 | チェルシー・セラピューティクス,インコーポレイテッド | Enzyme inhibitory compounds |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
WO2012064377A1 (en) * | 2010-03-29 | 2012-05-18 | Chelsea Therapeutics, Inc. | Antifolate compositions |
US8835445B2 (en) | 2010-06-02 | 2014-09-16 | Trius Therapeutics, Inc. | Dihydrofolate reductase inhibitors |
WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
CN102552271B (en) * | 2010-12-09 | 2014-08-06 | 中国科学院上海药物研究所 | Use of quinazoline compounds in preparation of drug for resisting flaviviridae viruses |
GB201104153D0 (en) * | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
TW201311149A (en) * | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | Pesticide |
SI3321265T1 (en) | 2015-03-04 | 2020-07-31 | Gilead Sciences, Inc. | 4,6-diamino-pyrido(3,2-d)pyrimidine compounds and their utilisation as modulators of toll-like receptors |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
MA46093A (en) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | TOLL-TYPE RECEIVER MODULATING COMPOUNDS |
TW202212339A (en) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TWI751516B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TW202115056A (en) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | Processes for preparing toll-like receptor modulator compounds |
AU2022425491A1 (en) | 2021-12-30 | 2024-07-04 | Byondis B.V. | Antifolate linker-drugs and antibody-drug conjugates |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028473A1 (en) * | 1979-11-01 | 1981-05-13 | Pfizer Inc. | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2945859A (en) * | 1960-07-19 | Diaminoquinazolines and method of | ||
GB1045180A (en) * | 1963-09-20 | 1966-10-12 | Parke Davis & Co | Quinazoline derivatives |
GB1141249A (en) * | 1967-05-25 | 1969-01-29 | Parke Davis & Co | New quinazoline compounds and methods for their production |
GB1161644A (en) * | 1967-09-11 | 1969-08-13 | Parke Davis & Co | Quinazoline Compounds and process means for producing the same |
US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
US3635979A (en) * | 1969-09-29 | 1972-01-18 | Pfizer | Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines |
DE2125907C3 (en) * | 1971-05-25 | 1980-12-18 | Bayer Ag, 5090 Leverkusen | Azo dyes, processes for their production and processes for dyeing and / or printing fiber materials |
JPS53103484A (en) * | 1977-02-21 | 1978-09-08 | Takeda Chem Ind Ltd | Quinazoline derivatives, process for their preparation and nsecticedes and fungicides |
US4377581A (en) * | 1980-03-03 | 1983-03-22 | Pfizer Inc. | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines |
US4298613A (en) * | 1980-05-05 | 1981-11-03 | E. I. Du Pont De Nemours And Company | Agricultural heterocyclic sulfenamides |
FI70411C (en) * | 1980-12-29 | 1986-09-19 | Pfizer | FORM OF ANTHYPERTENSIVE 4-AMINO-6,7-DIMETOXY-2-PIPERAZINOQUINAZOLE DERIVATIVES |
US4451466A (en) * | 1982-07-02 | 1984-05-29 | Shell Oil Company | Use of pyrroloquinazolinediamines as pesticides |
US4672116A (en) * | 1985-12-20 | 1987-06-09 | Ortho Pharmaceutical Corporation | Substituted 5,6-dialkoxyquinazoline derivatives |
US4677219A (en) * | 1986-07-17 | 1987-06-30 | Warner-Lambert Company | Substituted benzonitriles |
US4818753A (en) * | 1987-09-18 | 1989-04-04 | Sri International | Synthesis and method of use for 2, 4 diaminoquinazoline |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
IL89027A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
US5141941A (en) * | 1988-11-21 | 1992-08-25 | Ube Industries, Ltd. | Aralkylamine derivatives, and fungicides containing the same |
GB8910722D0 (en) * | 1989-05-10 | 1989-06-28 | Smithkline Beckman Intercredit | Compounds |
JPH0776316B2 (en) * | 1989-09-19 | 1995-08-16 | キヤノン株式会社 | Recording liquid |
-
1994
- 1994-02-14 IL IL10863094A patent/IL108630A0/en unknown
- 1994-02-16 AP APAP/P/1994/000620A patent/AP506A/en active
- 1994-02-17 EP EP94910694A patent/EP0684824A4/en not_active Withdrawn
- 1994-02-17 AU AU62986/94A patent/AU6298694A/en not_active Abandoned
- 1994-02-17 TN TNTNSN94014A patent/TNSN94014A1/en unknown
- 1994-02-17 WO PCT/US1994/001658 patent/WO1994018980A1/en active Application Filing
- 1994-02-17 MA MA23423A patent/MA23116A1/en unknown
- 1994-02-17 MX MX9401249A patent/MX9401249A/en unknown
- 1994-02-18 TW TW083101324A patent/TW315298B/zh active
- 1994-06-28 US US08/267,340 patent/US5534518A/en not_active Expired - Fee Related
-
1995
- 1995-04-20 US US08/426,541 patent/US5616718A/en not_active Expired - Fee Related
-
1996
- 1996-02-16 AP APAP/P/1996/000796A patent/AP507A/en active
- 1996-05-01 US US08/640,610 patent/US5874579A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028473A1 (en) * | 1979-11-01 | 1981-05-13 | Pfizer Inc. | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them |
Also Published As
Publication number | Publication date |
---|---|
TNSN94014A1 (en) | 1995-04-25 |
EP0684824A4 (en) | 1996-02-14 |
US5874579A (en) | 1999-02-23 |
AP9400620A0 (en) | 1994-04-30 |
MX9401249A (en) | 1994-08-31 |
TW315298B (en) | 1997-09-11 |
AU6298694A (en) | 1994-09-14 |
AP9600796A0 (en) | 1996-04-30 |
AP506A (en) | 1996-07-18 |
IL108630A0 (en) | 1994-05-30 |
WO1994018980A1 (en) | 1994-09-01 |
US5616718A (en) | 1997-04-01 |
US5534518A (en) | 1996-07-09 |
MA23116A1 (en) | 1994-10-01 |
EP0684824A1 (en) | 1995-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP507A (en) | Novel insecticidal 2,4-diaminoquinazolines. | |
JP3353895B2 (en) | Pest control pyrimidine compounds | |
EP0238711B1 (en) | Thiadiazabicyclononane derivatives, processes for their production and herbizidal compositions | |
DK165108B (en) | 3-Phenyluracils and enol ethers and salts thereof, process for preparing them, weed-killer which comprises these compounds, and the use of the compounds for controlling weeds | |
JPH0649689B2 (en) | 2-anilinopyrimidine derivative, method for producing the compound, and agrochemical composition containing the compound | |
CZ301369B6 (en) | Herbicidally active derivatives of 3-hydroxy-4-aryl-5-oxopyrazoline | |
JPH07165730A (en) | New agricultural chemical | |
KR0172947B1 (en) | Heterocyclic compounds | |
AU645193B2 (en) | Pyridine derivative, production thereof, herbicide and method of weeding | |
US5532367A (en) | Insecticidal pteridines and 8-deazapteridines | |
JPH08119807A (en) | Indoles as insect controller and tick controller | |
AU673222B2 (en) | Insecticidal 5-substituted-2,4-diaminopyrimidine derivatives | |
EP0046467B1 (en) | Quinoxaline derivatives and herbicidal composition | |
KR100497135B1 (en) | Herbicidal 2,6-disubstituted pyridine and 2,4-disubstituted pyrimidine | |
KR900000566B1 (en) | Photoactive azole pesticides | |
HU217994B (en) | Insecticidal and acaricidal (halogenalkylthio/sulfinyl and sulfonyl/)-arylpyrrole derivatives, compositions containing such compounds and use thereof | |
JPS6033112B2 (en) | Diphenyl-substituted pyrazolinones and their production methods and uses | |
JPS61130275A (en) | Pyridazinone derivative, preparation thereof, and insecticidal, miticidal and fungicidal agent | |
AP36A (en) | Pyrazoline insecticides | |
IL132831A (en) | Pesticidal and parasiticidal | |
JPH09176170A (en) | Microbicide | |
JPH0678339B2 (en) | Fused heterocycle derivative | |
JPH05201808A (en) | Nematocide composition | |
JPH0725857A (en) | Condensed heterocyclic derivative and herbicide | |
JP2530155B2 (en) | 2-Phenoxypyrimidine derivative and herbicide |